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List of abbreviations 
• µg   Microgram 
• µL   Microliter 
• µm   Micrometer 
• µM   Micromolar 
• AMD   Age-related macular degeneration 
• CME   Cystoid macular edema 
• CNV   Choroidal neovascularization 
• d   Days 
• DAPI    4´6´-diamidino-2-phenylindole 
• DME   Diabetic macula edema 
• DPBS   Dulbecco's phosphate-buffered saline 
• DR   Diabetic retinopathy 
• EDTA   (Ethylenedinitrilo)tetraacetic acid 
• EMA   European Medicines Agency 
• FDA   Food and Drug Administration 
• GCL   Ganglion cell layer 
• h   Hours 
• HCL   Hydrochloric acid  
• INL   Inner nuclear layer 
• IPL   Inner plexiform layer 
• MgCl2   Magnesium chloride 
• min   Minutes 
• NaCl   Sodium chloride 
• NP   Nanoparticle 
• ONL   Outer nuclear layer 
• OPL   Outer plexiform layer 
• PLA   Polylactic-acid 
• PLGA   Polylactic-coglycolic-acid 
• PRL   Photoreceptor layer 
• RPE    Retinal pigment epithelium 
• RVO   Retinal vein occlusion 
• TAE   Tris-acetate-EDTA 
• TBS    Tris buffered saline 
• Tris base  2-Amino-2-(hydroxymethyl)-1,3-propanediol 
• TUNEL  TdT-mediated dUTP-biotin nick end labeling 
• VEGF   Vascular endothelial growth factor 
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1. Introduction 
1.1. Anatomy of the eye 
The eye is the main sensory system for the perception of our environment. This 
complex function is made possible by a highly diverse organ consisting of various 
specified tissues. The following short introduction into the anatomy of the human 
eye is supposed to recapitulate the necessary information to understand the 
experiments conducted in this thesis.  
 
Figure 1 Schematic representation of the layers in the retina and their components; with 
kind permission of Hain, B.  
Although the Retina is only 0.1-0.5 mm thick, it is composed of many different 
layers (Figure 1). The most outer stratum and closest to the choroid is the retinal 
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pigment epithelium (RPE). Cells found in the RPE layer play an important role in 
a multitude of processes, including absorption of redundant light, several 
transport and buffering phenomena and the secretion of signaling molecules. 
Aside from that they are responsible for the phagocytosis of photoreceptor 
segment membranes and contribute to the immune privileged status of the eye. 
The next stratum towards the vitreous body is the photoreceptor layer (PRL). 
Here light signals are translated by rods and cones into electric pulses. Even 
further towards the interior, the outer limiting membrane separates the outer from 
the inner segments of the photoreceptor cells. In the following outer nuclear layer 
(ONL) the somata of these cells are found. Their axons reach into the outer 
plexiform layer (OPL) and make contact with the horizontal, bipolar and amacrine 
cells. This collection of cells is responsible for initial processing and modification 
of the signals. Their cell bodies are found towards the interior of the eye, in the 
inner nuclear layer (INL). In this layer also the Müller cells are situated. They 
provide structure and metabolites to the surrounding cells. In the following inner 
plexiform layer (IPL) all mediating cells pass on their information to the ganglion 
cells. Their somata are located in the ganglion cell layer (GCL) and their axons 
proceed parallel to the surface of the retina as the nerve fiber layer towards the 
optical nerve. On the inside of this layer the inner limiting membrane forms a 
barrier between the vitreous and the retina1. 
There are two locations in the retina that deserve special mentioning due to their 
particularly specific role. The first is the point where all the nerve fibers of the 
ganglion cells leave the eye, the optic disc. As there are solely axons in the 
position, no photoreceptors are found and no visual information is obtained from 
this point. Then, 15° temporal of the optic disc the macula lutea forms an oval pit 
in the retina. In this area a high density of cones is found in the photoreceptor 
layer. In its center the fovea centralis retinae is localized, which is specialized for 
sharp central vision and characterized by the absence of blood vessels.  
When studying the anatomy of the eye and the retina in specific, imaging through 
microscopy can be used for precise observation of the earlier described layers. 
Here, especially fluorescence microscopy offers great possibilities as dyes with 
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different colors can be used to monitor a multitude of structures or markers at the 
same time. Staining of the cell nucleus by 4’,6-diamidino-2-phenylindol (DAPI) is 
used to localize the different cells in the retina and distinguish the different layers 
(Figure 2). After treatment with DAPI the cell nucleus is visible under the 
microscope in a blue filter, as this color is the emission peak for the fluorescence 
of the dye. Then, coming from the vitreous body and going out of the eye the 
found layers of the retina are: ganglion cell layer (GCL), inner plexiform layer 
(IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer 
(ONL), photoreceptor layer (PRL) and choroid. Neither of the limiting membranes 
can be clearly identified due to exclusive nucleus staining. The sclera forms the 
outward boundaries of the bulbus, visible as a relatively consistent order of blue 
nuclei outside of the retina. Embedded into loose connective tissue, the sclera 
itself is embedded safely in the orbita. 
 
Figure 2 Layers of retina, sclera and connective tissue of a native ex-vivo pig eye. 
Designation of different layers added: coming from the vitreous body and going out of the 
eye the found layers of the retina are: ganglion cell layer (GCL), inner plexiform layer (IPL), 
inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), 
photoreceptor layer (PRL), choroid, sclera and connective tissue. 
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1.2. Diseases of the posterior segment  
In this paragraph three of the most frequently diagnosed retinal diseases are 
presented. These include age-related macular degeneration, diabetic retinopathy 
and retinal vein occlusion. They all have in common that one of their main 
treatment options involve intravitreal injections.  
1.2.1.  Age-related macular degeneration 
Age-related macular degeneration (AMD) is the most frequent cause of loss of 
eyesight after the 60th year of age in western countries. In all found cases about 
15 % of the patients have the exudative form, which is accompanied by choroidal 
neovascularization (CNV)2. Cases of visual impairment and blindness as a 
consequence of this ailment are estimated to increase from 620,000 in 2010 up 
to 1.6 million in 20503. The prevalence of this disease is 1.2 % amongst the 43 - 
86 year old people, with the majority of the patients being after their 75th life 
year4,5. Additionally, no difference is found between men and women regarding 
the prevalence. However, Caucasians are proven to hold a higher risk for the 
occurrence of AMD than other ethnicities6.  
In exudative AMD, pathological angiogenesis leads to visual impairment due to 
restructuring in the region of the macula. At the onset of the disease, deposits of 
the outer segments of the photoreceptors are accumulating in the pigment 
epithelium and change the composition of the proteins over lifetime, thereby 
forming senile plaques. This in turn leads to increased thickness of the Bruch’s 
membrane and as a consequence results in a higher diffusion resistance towards 
the choroidal epithelium. In exudative AMD it is assumed that a cascade initiated 
by this process that leads to the release of inflammatory markers, oxygen radical 
formations and numerous growth factors, such as the vascular endothelial growth 
factor (VEGF). These can be released by numerous ocular cells and fulfill a 
variety of functions such as stimulation of endothelial growth, promotion of 
vascular permeability and dissociation of tight junction components. As a result, 
small vessels that originate from the choroidal capillaries penetrate through 
lesions of the Bruch’s membrane and grow into the sub-retinal space and partially 
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under the retinal pigment epithelium. The originating vessels show pathologically 
degenerated cell structures, due to their immaturity which in turn causes leakage 
of exudates and blood constituents into the extravasal space7. Subsequently 
edema and cellular remodeling processes alter the surrounding areas and can 
be observed in the typical picture of exudative AMD during indirect funduscopy. 
The progression of this bilaterally occurring disease leads to decreased visual 
acuity, blurred vision, scotoma and ultimately to the loss of sight.  
For treatment, therapeutic strategies should be implemented as soon as possible 
in order to maintain a high visual acuity. For the majority of all exudative AMD 
cases the treatment option of choice consists of inhibition of the 
neovascularization via intravitreal injection of anti-VEGF medication. Momentarily 
the most commonly applied drugs are antibodies or antibody fragments that bind 
VEGF and thereby reduce the neovascularization. Examples here are aflibercept,  
ranibizumab or off-label bevacizumab7. These anti-VEGF treatments are 
currently the only therapeutic agents able to stabilize or improve vision in patients 
suffering from neovascular ocular ailments8. In the ANCHOR and MARINA 
studies it was successfully shown, that approximately 90 % of the patients that 
were treated with the anti-VEGF agent ranibizumab remained at a relatively 
consistent level regarding their visual acuity after twelve months of treatment. 
Reversely, this means that approximately 10 % were unable to stay on a stabile 
level concerning their visual acuity on anti-VEGF treatment whereas 30 % of the 
patients even increased their visual acuity under ranibizumab treatment9,10. 
Unfortunately, until now there is no treatment for the late stage of non-exudative 
AMD that is responsible for a slowly progressing macular atrophy, which is called 
geographic atrophy.  
1.2.2. Diabetic retinopathy 
Diabetic retinopathy (DR) is the most common cause for visual impairment or loss 
of sight in the industrial countries in working-age individuals. Around 4.1 million 
people in the U.S. suffer from diabetic retinopathy of which approximately 
900,000 developed a sight-threatening stage of the disease11. After disease 
duration of minimum 15 years more than 80% of the type one diabetes patients 
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and over 60% of the type two diabetes patients suffer from DR. Subsequently, 
approximately 24% with type one and 6% with type two diabetes develop 
proliferative DR12. 
 
Figure 3 Fluorescence angiography of a patient suffering from DR to depict the blood 
vessels of the ocular fundus, displaying typical pathologies of DR: I: neovascularization 
around the papilla; II: leakage of macromolecules (hard exudates); III: retinal bleedings; 
modified picture, obtained from Spitzer M., Images of the Universitäts-Augenklinik 
Tübingen.13 
From the pathophysiological perspective, DR is a micro vasculopathy of the 
retinal capillaries caused by a diabetic metabolic situation. Due to the local 
environment, capillary occlusion and deranged vascular wall permeability are 
observed, causing ischemia. All these factors together result in the release of 
I
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proangiogenic cytokines and sight-threatening changes in the retinal tissue 
(Figure 3). This has various consequences such as micro aneurysms, exudates, 
bleedings, edema, necrosis and neovascularization. Here, damage to the basal 
membrane and the vascular endothelium can be identified as the main factors for 
developing DR. Subsequently, the blood retina barrier breaks down and leakage 
of macromolecules and fluids accumulate in the intracellular space which may 
lead to diabetic macula edema (DME). As a consequence of the micro aneurysm 
and the bulges of the vascular walls, cytokines such as VEGF are released and 
may lead to pathological neoangiogenesis in order to compensate the insufficient 
supply of oxygen14. In this, the hyaloid membrane of the vitreous body functions 
as scaffold for the neovascularization.  
First line therapy of DR concerns systematic treatment of the causal reasons for 
this ailment. First to mention is the strict adjustment of the blood glucose levels. 
Another important parameter to take into consideration is reduction of the blood 
pressure. Local therapy often consists of laser treatment or administration of 
intravitreal injections that resolve the swelling of the leaking blood vessels. Initially 
monthly injections are necessary or post-laser checkups every three months15,16. 
However, it must be noted that recent studies have shown that intravitreal 
injection therapy with anti-VEGF antibodies or antibody fragments seems to be 
more effective than laser treatment15,17,18. 
1.2.3. Retinal vein occlusion 
Retinal vein occlusion (RVO) is the second most common retinal vascular 
disease of the eye after DR. The prevalence of retinal vein occlusion ranges from 
0.3 to 1.6 %. The blue mountain eye study examined the incidence of RVO in 
people above the age of 49 and found that after a period of five years 0.8 % of all 
monitored subjects were suffering from this vascular ailment whereas after ten 
years this had increased to 1.7 %19. Most patients suffering from this disease are 
diagnosed between their 60th and 70th year of life although there are also younger 
reported cases. 
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Figure 4 Fundus photography of a patient suffering from RVO highlighting typical disease 
pathologies: I: papilledema; II: dilatation and increased tortuosity of the retinal veins; III: 
ischemia; IV: streaky retinal bleedings; V: cystoid macular edema; modified picture, 
obtained from Spitzer M., Images of the Universitäts-Augenklinik Tübingen.13 
In the development of RVO, thrombotic changes in the vascular system cause 
intraluminal constriction of vessels, which results in an increase in pressure of the 
local venous system20. The diminished or absent drainage of the retinal veins, 
combined with the elevated pressure, leads to leakage of blood components into 
the retinal tissue. In the region around the central retinal vein this may lead to the 
typical extracellular cystoid macular edema (CME). Additionally, as a 
consequence of the restricted perfusion, local ischemia occurs (Figure 4). This is 
followed by the expression of permeability increasing cytokines (e.g. VEGF). 
Depending on the severity of the occlusion and the resulting ischemia, the 
induced edema which in severe ischemia may later be followed by 
neovascularization differs in intensity. Therefore, the symptoms observed in RVO 
are dependent on the extent of the occlusion and especially on its localization. 
Due to possible hemorrhages and edemas in the retinal tissue, symptoms of RVO 
I
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range from reduced vision acuity to a total loss of sight. In general, a branch 
retinal vein occlusion (BRVO) is approximately three times more likely to occur 
than the closure of the central vein (CRVO). Fortunately, less severe symptoms 
are associated with the former. Occlusions of the retinal veins itself are rarely to 
be remedied causally, e.g. thrombolysis is considered to be not effective for 
RVOs. 
Currently, in RVO therapy mainly the neovascular effects of the retinal vein 
occlusion and macula edema are treated21-23. Hence, intravitreal injection of anti-
VEGF medication is the treatment of choice.  
 
1.3. Drug delivery to the posterior segment today  
Successful delivery of pharmaceuticals to the posterior segment of the eye still 
remains a challenging task in the treatment of retinal diseases, despite advanced 
understanding of anatomical barriers and transport mechanisms. The main task 
of ocular drug delivery is to overcome these protective obstacles to achieve 
therapeutically relevant concentrations of therapeutic agents in the target tissues. 
In general, systemic and local treatments can be distinguished. In the field of 
ophthalmology the local application of medication is highly favored. There are two 
important reasons for this and both are related to the immune privileged status of 
the eye. Similar to the brain, the retina is separated from the circulating blood by 
a selective blood-retina barrier24. In here, tight junctions fulfill a special role in two 
different layers of tissue. The cells of the retinal pigment epithelium are connected 
by a belt of tight junctions at the basal pole. These contact sites form channels 
between the cells but also heavily restrict diffusion. They form the first component 
in the blood-retina barrier. The second part consists of the endothelial lining of 
the intraretinal blood vessels also showing tight junctions with similar 
characteristics as to those found in the RPE. These two components work in 
synergy and heavily limit the diffusion of compounds from the blood to the retina. 
As a result, systemically utilized drug substances will hardly be able to reach their 
target tissue. It has previously been shown that after systemic administration of 
a drug, less than 2 % reaches the vitreous body25. The second major reason why 
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local drug application is preferred is because systemic adverse effects can be 
precluded. For administration of drugs to the eye the following routes are mostly 
used:  
• Topical application 
• Intravitreal injections 
• Periocular injections 
Their advantages and disadvantages will be discussed below. 
1.3.1. Topical application 
For topical treatment eye drops offer an elegant method for therapy of anterior 
segment diseases due to their ease of application and good tolerability. However, 
only very low amounts of active substance can be found in the posterior segment 
of the eye after using this application form. Approximately only 0.1 ‰ of the drug 
detected in tear fluids penetrates deep enough to reach the retina and the 
choroid26. The main reasons for this are firstly, the corneal clearance, consisting 
of lacrimation and tear transition25 and secondly, that to reach the posterior 
segment the medication first has to diffuse through the cornea. The cornea is 
composed of several layers that serve to prevent this. Additionally, after passing 
the cornea the medication needs to circumvent lymphatic clearance27. Due to the 
very low efficiency of delivery, eye drops only play a minor role in the treatment 
of posterior segment diseases. For example, prevention and treatment of the 
cystoid macular edema (CME) can be performed via eye drops. Nevertheless, 
the benefit and efficiency of this intervention is still discussed28. 
In order to improve eye drops, efforts have been made to develop contact lens 
systems which contain certain medication or increase the uptake of medication 
into the eye. Recently, molecular imprinted polymeric gels have been tested 
successfully for contact lens mediated enhanced drug delivery29,30. In addition, 
conjugation of nanoparticles or liposomes with contact lens is a novel approach 
that is currently investigated31. However, most of these recent findings mainly 
prove local efficacy and do not show sufficiently high drug levels at the retina. 
Introduction 
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Therefore, drug delivery to the posterior segment through eye drops remains 
difficult.  
1.3.2. Intravitreal injections 
In order to obtain a sufficiently high concentration of medication at the retina, pars 
plana intravitreal injections are currently the most efficient application technique. 
It is the method of choice for intraocular administration of antibiotics32, 
corticosteroids33, chemotherapeutic agents34 and anti-VEGF medication35,36. 
When performing an intravitreal injection, a thin needle perforates the limbus and 
enters the vitreous between the corpus ciliare and the retina. After injection of the 
drug, a concentration equilibrium is first established, after which a loss of the 
medication occurs37. The blood retina barrier works in favor of the approach, as 
loss through the blood circulation is prevented24. Unfortunately, after injection the 
drug molecules are still eliminated rapidly via the circulating aqueous humour, 
leading to the excretion through the canal of Schlemm. Another route of removal 
is the retina itself, where the medication is removed from the eye utilizing active 
transport mechanisms38. The half-life period of substances in the vitreous body 
is mainly depending on its molecular weight, but also on the status of the vitreous 
space (e.g. shorter drug half-life in vitrectomized eyes). Most drugs with low 
molecular weights only possess a short half-life in the range of several hours39. 
Therefore, often very high doses are necessary to be able to keep a clinically 
relevant concentration in the posterior segment over a significant amount of time. 
However, high doses increase the chance of side effects. Inevitably, this leads to 
the need of numerous re-injections. Serious side effects such as retinal 
detachment, hemorrhage40, increased intraocular pressure41, endophthalmitis42 
or cataracts43 though rarely occurring endanger successful outcome of the 
therapy and affect patient comfort. For example, after intravitreal application of 
VEGF such side effects have been observed in 0.1-0.2 % of the treated 
patients44. Nevertheless, intravitreal injections are currently the preferred route of 
administration for many indications, including AMD.  
Recently, depot or slow-release systems have been developed that enhance the 
problematically short half-life observed after intravitreal injection. Currently in use 
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are implants composed of polymers with slow release characteristics for the 
encapsulated drugs45. In here one can distinguish between biodegradable and 
non-biodegradable devices. Examples are Ozurdex® (Dexamethason), Vitrasert® 
(Ganciclovir) and Retisert® (Fluocinolone Acetonide), which are all approved for 
clinical employment. The implant devices can be injected into the vitreous or be 
positioned in the pars plana tissue itself. Advantages of these drug delivery 
vehicles are numerous. First and foremost, the desired drug concentration can 
be held on a consistent level over a longer period of time providing the necessary 
medication dosage. Second, a lower incidence of local complications such as 
infections or lens damage is expected due to reduced frequency of injections46. 
Finally, they often also offer more consistent drug release. Nevertheless, it has 
to be noted that the devices that are not bio-degradable may require surgical 
removal. In the future different locations for placement of the implants might be 
leading to even more beneficial dosing. For example, choroidal, conjunctival and 
scleral tissue might be future targets, but also subcutaneous implants could be 
useful in future therapy for retinal diseases47. 
1.3.3. Periocular injections 
Among periocular injections one can distinguish between retrobulbar, peri- 
bulbar, subtenon and subconjunctival injections. Administration via this route may 
offer a chance to enhance drug delivery to the posterior segment48. Recently, it 
has been shown that the subconjunctival application leads to 54 times higher 
medication levels compared to systemic injections, showing the significant 
advantage of this technique over systemic application49. Another benefit of this 
application method is that these injections are far less invasive than intraocular 
injections, thereby reducing the risk of complications. After periocular application, 
the medication reaches the target structures of the posterior segment via 
transscleral or transcorneal diffusion and through local blood circulation50. The 
sclera covers the vast majority of the overall surface of the bulbus and therefore 
offers a large absorption area. Additionally, it is more permeable to drug 
molecules than the conjunctival and corneal tissue, which is advantageous for 
delivery purposes51. Similar to the diffusion from the eye, the passage capacity 
of molecules is mainly defined by their molecular weight. As such, small 
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molecular compounds are favored over larger antibodies for periocular injections. 
Currently, predominantly lipophilic, long lasting corticosteroids are applied with 
this technique. Therefore, diseases treated with this modus are first and foremost 
posterior uveitis or other inflammatory vessel or retinal diseases. Possible side 
effects that are observed after applying this therapeutic approach are an 
increased intraocular pressure, hyphema, strabismus and corneal 
decompensation25. In order to attain higher intraocular drug concentrations over 
a longer period of time, episcleral depots can be employed. These function in a 
similar manner as the intravitreally injected depots described above. 
 
1.4. DNA based nanoparticles  
Nanoparticles can be formulated out of various different materials and have 
recently been receiving more and more attention in the field of drug delivery due 
to their versatile nature. They may vary in size from 10 to 100 nm and in contrast 
to macroscopic objects, these submicron vehicles exhibit special properties due 
to their high surface area and the large influence of Brownian motion. In 
combination with potential targeting mechanisms these submicron properties are 
especially desired in tissues where physiological barriers hinder establishing 
therapeutically relevant concentrations of agents – such as in the posterior 
segment of the eye. Manufacturing them out of DNA provides many advantages 
over other materials. For example, the size and structure of liposomes and 
microspheres are often greatly differing, which can hinder efficient therapy. The 
self-recognition properties of DNA constitute molecules uniform in size and 
functionality. They can be designed into desired shapes with control over spatial 
orientation, thereby assuring the required characteristics. Additionally, nucleic 
acid nanoparticles have not yet been investigated for the use of intravitreal drug 
delivery devices thus far.  
In this work nanoparticles constructed from different amphiphilic oligonucleotides 
are employed to investigate their potential in ocular drug delivery. The DNA 
sequences differ in their respective total length, number of hydrophobic 
modifications and sequence. To incorporate non-water-soluble entities, 
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dodecyne-modified deoxyuracil are coupled onto the growing oligonucleotide 
chain at the terminal end during DNA synthesis (Figure 5-I). Microphase 
separation enables the amphiphiles to self-assemble into micellar structures 
when introduced into an aqueous medium (Figure 5-II). Inside the formed 
micelles a lipid core is located consisting of the alkyl tales of the modified 
deoxyuridine nucleotides, which are shrouded by single stranded DNA in the 
corona. The micellar construct as described above will from hereon be referred 
to as nanoparticles (NPs). Hybridization with complementary oligonucleotides 
offers the possibility of facile binding of a therapeutic agent or a fluorophore for 
imaging purposes to these NPs (Figure 5-III).  
 
Figure 5 Schematic representation of the different steps of NP-assembly: I: incorporation 
of dodecyne-modified deoxyuracils at the terminus of the oligonucleotide chain; II: self-
assembly of the amphiphilic DNA into micellar structures (NP) in aqueous medium; III: 
hybridization of the NP with complementary oligonucleotides functionalized with a 
covalently bound fluorophore; modified image, obtained from Vries, J.W.d., DNA 
Nanoparticles as Ocular Drug Delivery Platform.52 
The formed NPs have an approximate diameter of 12 nanometer (nm). However, 
this parameter can be modulated by altering the sequence length of the 
amphiphilic oligonucleotides. The micellar structures consist of an average of 25 
lipid-DNA oligonucleotides53.  
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Figure 6 Schematic representation of different options of NP loading. I: loading of the NP 
via hydrophobic interactions inside the lipid-tail core; II: hybridization with the 
complementary DNA that is covalently functionalized with the molecule of interest; III: 
adaptive binding of an agent utilizing an aptameric sequence; modified image, obtained 
from Vries, J.W.d., DNA Nanoparticles as Ocular Drug Delivery Platform.52 
For loading of actives, these NPs offer diverse options (Figure 6). Firstly, lipophilic 
interactions can be used to load hydrophobic medication in the core of the NP. 
Aside from that covalent binding of therapeutic agents to the complementary 
strand provides a convenient option. However, this involves chemical 
modification of the target compound, which may lead to an inactive or even toxic 
drug. A third and more elegant method is the loading of NPs via an aptamer 
hybridized to the single stranded corona, enabling the drug delivery of almost any 
drug. Aptamers are oligonucleotides which fold around a target molecule to form 
an adaptive binding. The target is kept in place by electrostatic interactions, 
hydrogen bonds and base stacking. 
The safety of the used NP platform has been tested in different ocular cell lines 
in previous experiments with no toxic effects detectable. Additionally, in-vivo 
studies have also been performed with single and multiple exposures at various 
concentrations of NPs. Apoptosis screening was undertaken using TdT-mediated 
dUTP-biotin nick end labeling (TUNEL) staining showing no increased cellular 
damage under the influence of the applied NPs52. 
I II III
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All the presented options for modification, loading and the promising properties 
due to their small size led to the hypothesis that these DNA based NPs can be 
employed as a versatile drug delivery platform for ocular therapy of posterior 
segment diseases.   
Introduction 
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1.5. Thesis motivation and overview 
Eyesight is the main medium of perception of our environment. As a consequence 
our eyes are embedded and protected by numerous different tissues and barriers, 
extraordinary in anatomy and physiology. Therefore, efficient drug delivery to the 
posterior segment of the eye remains a challenging task until today and is a major 
obstacle in the field of ophthalmology that needs to be overcome. Incorporating 
DNA nanostructures for drug delivery combines the potential of submicron 
attributes with the versatility of nucleic acid. This combination employed in the 
field of ophthalmology will certainly lead to more opportunities for research in 
treatment development. The ability to design base sequences in order to utilize 
certain attributes of DNA holds manifold options and potentials for therapies in 
the future. 
The purpose of the work was to investigate the behavior of novel lipid-modified 
DNA nanoparticles (NPs) injected into the vitreous body and periocular tissue. 
First the intravitreal application of lipid DNA NPs as a novel type of drug delivery 
platform was investigated. Here, the defined NPs were introduced in the 
approximate center of the vitreous body of ex-vivo porcine eyes. Afterwards, the 
behavior in regard to diffusion and retention of the vehicles was investigated 
utilizing a fluorophotometer. The next step in the examination of the utilized NPs 
was to define the ocular adhesion areas and variations in adhesion duration 
under ex-vivo conditions under the fluorescence microscope.  
After studying the diffusion and retention of the NPs in an ex-vivo setting, the 
same parameters were examined in-vivo. Therefore, a rat eye model was 
employed and the same defined drug delivery vehicles were injected into the 
posterior segment. The analysis of adhesion areas and variations in adhesion 
duration of the different NPs was performed as described above. 
Finally, the lipid DNA NPs were applied through subconjunctival injections into 
the periocular tissue. This was done in order to evaluate this administration 
technique in regard to its depot function and local distribution of the carrier. The 
adhesion areas and duration of presence were tested in the same in-vivo model 
as used before.  
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2. Materials and Methods 
2.1. Reagents and consumables 
• 0.9 % NaCl, Fresenius Kabi Deutschland GmbH 
• 2-Amino-2-(hydroxymethyl)-1,3-propanediol (Tris base), Roche 
• 4’,6-diamidino-2-phenylindole (DAPI), Invitrogen # D1306  
• Atipamezole 5.0 mg/ml, Albrecht GmbH 
• Atto-488 labelled complementary DNA at HPLC grade purity, Biomers.net 
• Conjuncain: Conjuncain®, EDO®, (4.0 mg/mL 
Oxybuprocainhydrochlorid), Bausch and Lomb GmbH, Berlin, Germany 
• Cover glasses 24x50 mm, R. Langenbrinck Labor- & Medizintechnik 
• Dulbecco's phosphate-buffered saline (DPBS), GIBCO® 
• Eppendorf tubes, Eppendorf® 
• (Ethylenedinitrilo)tetraacetic acid (EDTA), Sigma-Aldrich # 1233508 USP 
• Fentanyl 50 µg/ml, Albrecht GmbH 
• Flumazenil Kabi 0.1 mg/ml, Fresenius Kabi Deutschland GmbH 
• FluorSave, Calbiochem 
• Gentamicin, Gentamicin-POS® (5.0 mg/mL Gentamicinsulfate), 
Ursapharm GmbH 
• Glacial acetic acid, Sigma # A6283 
• Glass slides “Superfrost plus”, R. Langenbrinck Labor- & Medizintechnik 
• Hydrochloric acid solution (HCL), Sigma # 30723 
• Magnesium chloride (MgCl2), Sigma # M8266 
• Medetomidin 1.0 mg/ml, Albrecht GmbH 
• Methanol, AnalaR® NORMAPUR® # UN 1230 
• Midazolam 5.0 mg/ml, Hameln Pharmaceutical GmbH 
• Mydriatic agent, University Pharmacy Tübingen, (9 mL containing: 
Phenylephrin-HCL (225 mg), Tropicamid (45 mg), Povidon 25 (270 mg), 
Aqua ad. inj. (8.36 g)) 
• Naloxon 0.4 mg/ml, Hameln Pharma Plus GmbH 
• Pipetting tips (20 μl, 100 μl, 1000 μl), Greiner bio-one 
Materials and Methods 
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• Sodium chloride (NaCl), Sigma # S7653 
• Tissue-Tek O.C.T., Sakura Finetek 
• Ultra-pure water (Resistivity ≥ 18.2 MΩ), Merck millipore 
2.2. Equipment 
• 10 µL Syringe, Model 1701 RN SYR, Small Removable NDL, 32 gauge, 2 
in, point style 3, Hamilton 
• 50 µL Syringe, Model 1705 RN SYR, Small Removable NDL, 22 gauge, 2 
in, point style 2, Hamilton 
• Cryostat, Leica CM 1900, Leica Microsystems GmbH  
• Fluorotron Master™, Ocumetrics 
• Magnetic stirrer COMBIMAG RCT, IKA 
• Micro-pipettes , Eppendorf® 
• Microscope, Axioplan 2 Imaging, including Openlab software 
(Improvision), Zeiss 
• Ophthalmology surgical retroskop opmi cs-xy S4, Zeiss 
• Thermocycler UnoCycler VWR 732-1200, VWR International GmbH 
2.3. Buffers 
Preparation of TAE stock 
First, 14.6 g EDTA and 242 g tris base were dissolved in 800 mL of ultra-pure 
water while stirring. Afterwards, acetic acid was added to adjust the pH of the 
solution to 8.0. Finally, ultra-pure water was added to obtain a total volume of 1 L.  
Preparation of NP buffer stock 
400 µL of NP stock buffer was prepared by adding 100 µL of TAE stock 
(described above), 300 µL of MgCl2 (1 M) and 100 µL of NaCl (5 M) into an 
Eppendorf tube.  
Preparation of 1x TBS buffer 
For preparation of the TBS buffer 87.66 g NaCl and 60.57 g tris base were 
dissolved in 800 mL of ultra-pure water, using a magnetic stirrer until a clear 
solution was obtained. Afterwards, 25 % HCl was titrated to adjust the pH to 7.4. 
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Ultra-pure water was added until reaching a total amount of 1 L of the 10x 
solution. For further use a dilution of 1:10 in ultra-pure water was performed. 
2.4. Methods 
2.4.1. Preparation of NPs 
NPs were prepared in Eppendorf tubes in NP buffer by combining the desired 
amount of ultrapure water, NP buffer stock (described in section 2.3), the lipid 
oligonucleotide of interest and its fluorescently labeled complementary sequence 
bearing an Atto-488 dye on the 5’ end. For the NP stock buffer 2 µL was added 
to 98 µL final solution to obtain a final concentration of 8 mM Tris-Acetate, 1 mM 
EDTA, 20 mM NaCl and 12 mM MgCl2, pH 8.0. The NPs were prepared at a 
concentration of 20 µM. For functionalization equimolar amounts of 
complementary DNA strand were used. Finally, NPs were formed and hybridized 
using a thermal gradient. In a thermocycler the NP solutions were heated up and 
kept at (90 °C for the duration of 30 minutes). Afterwards, they were cooled down 
by 1°C every two minutes until room temperature was reached. NPs were stored 
in the dark at room temperature until further use.  
2.4.2. Fluorophotometric measurements 
In order to measure the fluorescence in the vitreous of the utilized eyes an ocular 
fluorophotometer was employed (Fluorotron Master™, Ocumetrics, Mountain 
View, CA). Before measurements were performed, the eye of interest was aligned 
with the lens of the system and the optical axis of the Fluorotron Master™. A blue 
laser is emitted through the optics of the fluorophotometer which leads to 
excitation of the fluorophore molecules. These in turn emit fluorescent green light 
that is recognized by the incorporated photodetector and measured at the point 
of intersection. The fluorescence was recorded in 0.25 mm sections along the 
determined optical axis by a program which converts the reading to the 
corresponding concentration. Thereby, a profile is generated that shows the 
fluorescence intensity as a function of the distance from the retina. 
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2.4.3. Evaluation of results obtained from fluorophotometric 
measurements  
To investigate the diffusion behavior of different NPs, it is important to note that 
the integrated fluorescence intensity obtained from the fluorophotometric 
measurements requires normalization. In order to detect the NPs, they were 
functionalized with the fluorescent dye Atto-488, which was attached via covalent 
binding to the complementarily strand. This strand was then hybridized to the 
NPs, thereby obtaining the fluorescently labeled vehicle. Binding of this dye to 
the DNA requires chemical modification of the structure of this molecule which 
leads to alteration of its fluorescence strength. The magnitude of those changes 
is dependent on the sequence of the DNA it is coupled to. As the NPs constitute 
unique sequences (different length and different amounts of lipid modified bases), 
the dye exhibits specific intensities for each NP. This means that the fluorescence 
intensity measured for one NP cannot be directly compared to the next, or to the 
free dye. In order to make the found results for the NPs comparable, for each an 
individual starting value was defined which represents 100 %. All the following 
measurements of the specific NP structure were divided by this first value, 
generating a relative value which can be compared between the different NPs. 
For normalization two different starting values were utilized. The first 
normalization was performed by measuring the respective NP in solution within 
a cuvette before injection using the cuvette holder of the fluorophotometer. This 
value gives information about the total injected amount and which fraction is 
detected. It will from hereon be given as the “solution” measurement. The second 
one was measured directly after injection, which is displayed in the later figures 
as the “instant” time point. This value gives insight in the time dependent 
distribution of the NPs in the vitreous body. Both normalization methods were 
utilized in order to compare the NPs. 
For all eyes investigated, the mean value and standard deviation were calculated 
for each time point using Excel 2010. The statistical significance was calculated 
utilizing JMP 13. Here, analysis of variance (ANOVA) and Dunnett’s post-hoc 
tests were performed. The small molecule control (Atto-488) data served as 
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“control”. Significances are displayed in the graphs of the discussion as: * for the 
value of P ≤ 0.05, ** for the value of P ≤ 0.01 and *** for the value of P ≤ 0.001. 
In the interest of clarity the statistical evaluation is incorporated in the Discussion 
(4.1.1). 
For the ex-vivo experiments the investigated time points were before injection 
and after 0, 5, 15, 30 minutes as well as after 4, 8 and 24 hours of incubation 
(n=6-8) (see section 2.4.5). In-vivo measurements were also performed before 
injection and 0, 1, 3 and 5 days post injection (n=6) (see section 2.4.6). 
2.4.4. Intravitreal injection of lipid-modified DNA NPs into ex-vivo 
pig eyes  
Porcine eyes, freshly obtained from the local abattoir were kept at a temperature 
of 4 °C and treated within 4h after delivery. Before administration of NPs or 
control, the eyes were shortly washed with ultra-pure water and left to adjust to 
room temperature. For NP administration, the eyes were placed on the bottom of 
a petri dish and fixated with one hand. Afterwards, the pars plana was penetrated 
approximately 4 mm posterior to the limbus of the eye using a needle of 30 gauge. 
Then, 40 µL of NP solution (20 µM) was injected into the center of the vitreous 
body under microscopic observation (Ophthalmology surgical retroskop opmi cs-
xy S4, Zeiss). The porcine eyes were then incubated for the designated time 
points in PBS buffer. 
For fluorophotometric evaluation, measurements were performed as described in 
2.4.2, before injection and after 0, 5, 15, 30 minutes as well as after 4, 8 and 24 
hours of incubation(n=6-8). 
For microscopy, the porcine eyes (n=3) were embedded in Tissue-Tek and 
subsequently frozen in liquid nitrogen after 5, 15, 30 minutes, 1 or 2 hours of 
incubation. Afterwards, cryosections were prepared, stained and imaged as 
described in 2.4.7. 
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2.4.5. Intravitreal injection of lipid-modified DNA NPs into in-vivo rat 
eyes  
Adult Lister Hooded Rats were obtained from Charles River (Germany) and 
treated according to the German animal protection law (Research permission AK 
3/11 and 1/15 to Sven Schnichels). Before treatment the animals were 
anesthetized by peritoneal injection of a three components anesthesia 
(0.1 mL/10 g bodyweight). For this, 5 mL of the anesthesia was prepared using 
0.5 mL Fentanyl (0.005 mg/kg), 2.0 mL Midazolam (2.0 mg/kg), 0.75 mL 
Medetomidin (0.15 mg/kg) and 1.75 mL of 0.9 % NaCl. Afterwards, the eyes were 
dropped with Conjuncain (4.0 mg/mL Oxybuprocainhydrochlorid, Bausch and 
Lomb GmbH, Berlin, Germany) further ensuring local anesthesia, and a mydriatic 
agent (University Pharmacy Tübingen, - 9 mL containing: Phenylephrin-HCL (225 
mg), Tropicamid (45 mg), Povidon 25 (270 mg)) in order to increase visualization 
during microscopic observation of the position of the injection needle. For 
intravitreal application 10 µL of NP solution (20 µM) were injected into vitreous 
body, approximately 3 mm posterior to the limbus using a 30 gauge needle.  
After the surgery, an antidote was employed subcutaneously to terminate the 
anesthesia (0.3 mL/10 g bodyweight). For the preparation of 15 mL of the 
antidote, 1.5 mL naloxon (0.12 mg/kg), 10 mL flumazenil (0.2 mg/kg) and 0.75 
mL atipamezol (0.75 mg/kg) were added to 2.75 mL of 0.9 % NaCl. Finally, 
gentamycin ointment was applied onto the injection site to prevent infection. For 
the following fluorophotometric measurements and fluorescence imaging 
different time points were investigated. 
For fluorophotometric evaluation, measurements were performed pre injection 
and 0, 1, 3 and 5 days post injection as described in 2.4.2. In order to do so, the 
living rats was anaesthetized as described above and the eyes (n=6) were dilated 
using mydriatic agent. The anesthesia was terminated by injection of the antidote.  
For microscopy the rats were euthanized with carbon dioxide inhalation after the 
designated time periods of 0, 5, 1, 3 and 5 days. The treated eyes (n=6) were 
enucleated, frozen in Tissue-Tec and further processed as described in 2.4.7.  
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2.4.6. Injection of lipid-modified DNA NPs into periocular tissue of in-vivo 
rat eyes 
For these experiments Adult Lister Hooded Rats were treated similar as those 
described in 2.4.5. Also the anesthesia was prepared and performed as 
described above. In order to additionally ensure local anesthesia, conjuncain (4.0 
mg/mL Oxybuprocainhydrochlorid, Bausch and Lomb GmbH, Berlin, Germany) 
was dropped topically at the site of the injection. Administration of 40 µL NP 
solution (20 µM) into the periocular tissue was performed subconjunctivally. A 30 
gauge needle was inserted 5 mm into the conjunctival tissue approximately 10 
mm temporolateral from the most lateral point of the limbus under microscopic 
observation. Antidote prepared as described above and administered at 0.3 
mL/10 g bodyweight was administered subcutaneously to end the anesthesia 
after surgery. In addition gentamycin eye drops were applied locally. The rats 
were euthanized with carbon dioxide inhalation after the designated time points 
of 30 minutes, 2, 4 and 24 hours as well as three days. The treated eyes including 
the surrounding subconjunctival tissue were then excised, frozen in Tissue-Tec 
and further processed as described in 2.4.7. Throughout the different time points 
in this experiment the analyzed eyes always equaled n=2, except for the time 
periods of one and three days where for U4T-18 and U6T-12 n=6 eyes were 
examined. 
2.4.7. Fluorescent microscopy and imaging  
Frozen sections of Tissue-Tek O.C.T. (Sakura Finetek) embedded porcine and 
rat eyes were longitudinally cut (12 µm) on a cryostat (Leica CM 1900), thaw-
mounted onto glass slides (Superfrost plus, R. Langenbrinck Labor- & 
Medizintechnik) and stored at -30 °C until further use. For visualization each 
section was fixed with 300 µL methanol (ten minutes) and afterwards washed 
with 1x TBS solution (3 x 3 minutes). In a next step the nuclei were counterstained 
with 100 µL 0.4 µg/mL DAPI (five minutes), before being washed with 1x TBS 
buffer (3 x 3 minutes) once more. After drying, the stained slides were covered in 
FluorSave (Calbiochem) and furnished with cover glasses (R. Langenbrinck 
Labor- & Medizintechnik). Finally, the prepared sections were imaged using a 
fluorescent microscope (Axioplan 2, Zeiss with Openlab software, Improvision). 
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The nucleus stain was imaged employing a small band DAPI filter (wavelength of 
emission maximum: ~461 nm), whereas the fluorescent dye conjugated to the NP 
was captured utilizing a FITC small band filter (wavelength of emission maximum: 
~495/519 nm). The obtained layers were combined to visualize the location of the 
dye with respect to the tissue of the posterior segment. In order to comprehend 
sizes a scale was introduced into the pictures indicating 130 µm of length. This 
scale was inserted using Microsoft Paint for Windows 10. The Openlab software 
gives information about how many pixels in which magnification add up to which 
size. For the 50 times magnification that was used for the imaging in this thesis, 
the amount of 100 pixels resembles 130 µm. 
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3. Results 
To investigate the suitability of DNA based NPs as a treatment modality for 
diseases of the posterior segment their half-life time and adhesion capacity to 
specific ocular tissues were tested. To gain initial insight in these properties, a 
variety of NPs were first injected in ex-vivo porcine eyes and their diffusion and 
adherence was monitored by fluorescence photometry and microscopy, 
respectively. Afterwards, this experimental setup was translated into in-vivo rats. 
The same parameters were investigated after intravitreal injection of several NPs 
that showed superior properties in the ex-vivo setup. Finally, to explore the use 
of this platform for delivery using a periocular administration route, they were also 
employed in sub-conjunctival injections. 
In order to gain insight in how the structural properties of these NPs relate to their 
adhesion capabilities, several NPs were designed. The sequences details of lipid-
modified oligonucleotides that were employed are displayed in Figure 7.  
 
Figure 7 Sequence and details of lipid-modified oligonucleotides used for NP preparation.  
As can be seen, the name of the respective NP already partially reveals the 
characteristics of the oligonucleotide. First, the letter “U” indicates the use of the 
lipid modified nucleotide. Next, the number following the U gives the total amount 
of modified deoxyuridine nucleotides in the sequence. The letter “T” in the name 
reveals that the modified bases are located on the terminus of the oligonucleotide, 
starting from 5’-end. Finally, the number in the end gives the total amount of 
nucleotides in the sequence.  
Name Sequence(5‘→ 3‘)
Lipid modified Bases
# (%)
U4T-12 UUUUGCGGATTC 4(33)
U4T-18 UUUUGCGGATTCGTCTGC 4(22)
U6T-12 UUUUUUGGATTC 6(50)
U6T-18 UUUUUUGCGGATTCGTCT 6(33)
U6T-20 UUUUUUGCGGATTCGTCTGC 6(30)
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In the following experiments, the NPs were formed by preparing the 
oligonucleotide of interest together with the complementary sequence, both at a 
concentration of 20 µM. Afterwards they were thermally cycled in order to form 
uniformly sized NPs that can directly be employed for intravitreal or sub-
conjunctival injections. As a first step the diffusion behavior of the different NPs 
was investigated in an ex-vivo setup. 
3.1. Intravitreal injection of lipid-modified DNA NPs into ex-vivo 
pig eyes 
3.1.1. Examination of diffusion of DNA NPs within an ex-vivo vitreous body 
Different NPs were injected into the vitreous of the ex-vivo pig eyes and the 
fluorescence signals were quantified inside the eye using an ocular 
fluorophotometer. As described in 2.4.2 this device is able to measure the 
intensity as a function of depth by sequentially focusing on points along the optical 
axis (from retina to cornea) in the ocular cavity. It then combines these signals 
into a fluorescence profile which is directly proportional to the concentration of 
the used NP. In Figure 8 an example of the data obtained from a typical 
fluorescence measurement is displayed. The first measurement was made 
directly after injection of the NP. Afterwards, the signal was measured at 5, 15, 
30 minutes (min) and 2 hours (h).  
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Figure 8 Fluorescence intensity (y axis) measured at different time points after intravitreal 
injection of U4T-18 NPs along the optical axis (x axis) in ex-vivo porcine eyes. The 
decreasing intensity over time indicates diffusion of the NPs into the vitreous body 
As can be seen, directly after injection of the NPs the highest signal was obtained 
in the vitreous body (Instant). The maximum fluorescence intensity here was 
approximately 270 units. As the fluorescence intensity is strongly dependent on 
the device and setup in which it is measured, no SI units could be given. However, 
throughout this thesis the experimental setup was kept constant. Therefore, 
values found for the different NPs could be compared amongst each other. In 
Figure 8 also a steady decrease of the signal was observed over time, indicating 
diffusion of the carrier from the ocular cavity. 
To quantify and compare the amount of NP present, the fluorescence intensity in 
the vitreous body at a given time point was integrated and normalized as 
explained in 2.4.3 for all eyes (n=6-8).  
As small molecular control to the NPs, the free Atto-488 was used. The integrated 
intensity of the control dye was compared with the initial intensity (solution) in 
order to obtain more insight in the total amount of molecules present in the 
vitreous body (Figure 9). 
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Figure 9 Integrated fluorescence intensity normalized to the solution measurement (y axis) 
at different time points after injection of Atto-488 control dye (x axis) into the vitreous body 
in ex-vivo porcine eyes (n=6), standard deviation added. The sudden drop from the 
solution measurement to the instant time point can presumably be explained by the 
dilution of the dye by the vitreous fluid. The normalization to the solution value shows that 
the control rapidly diffused into the vitreous body.  
As expected, the intensity of fluorescence decreased over time with an initial 
sudden drop. The intensity of fluorescence detected in the eye right after injection 
was only 22 % of the solution value. Furthermore, after five minutes the measured 
value already dropped down to 19 %, whereas after two hours the detected 
intensity of fluorescence was only 7 %.  
In order to be able to directly compare this data with different NPs, normalization 
was also performed to the initial measurement taken directly after injections 
(Figure 10). To relate the measured fluorescence after injection to the situation 
before treatment, the native fluorescence of the employed porcine eyes was also 
incorporated into the graph (prescan). 
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Figure 10 Integrated fluorescence intensity normalized to the instant measurement (y axis) 
at different time points after injection of Atto-488 control dye (x axis) into the vitreous body 
in ex-vivo porcine eyes (n=6), standard deviation added. The strong decrease of detected 
fluorescence over time indicates rapid diffusion of the control into the vitreous body. 
After one hour the fluorescence intensity was detected to be at 58 % of the instant 
fluorescence, whereas after eight hours the detected intensity of fluorescence 
was only around 11 %. Finally, after 24 hours the intensity has dropped to 4 %. It 
must be noted here that the peak detected after this period of time was only 
marginally above the prescan measurement (1%). This data indicates a very 
rapid diffusion of the control compound from the injection point into the vitreous 
body. 
After measurement of the small molecular control, the comparison with the 
different NPs could be made. The first lipid-DNA NP that was investigated was 
U4T-12. This NP sequence consists a total of twelve nucleotides, of which four 
contain a lipophilic modification. For the experiment porcine eyes were prepared 
and injected in the same fashion as described in in 2.4 and the fluorescence was 
measured at different time points after injection. Afterwards the fluorescence 
signal was normalized to the fluorescence intensity of the U4T-12 solution before 
injecting (Figure 11). 
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Figure 11 Integrated fluorescence intensity normalized to the solution measurement at 
different time points after injection of the U4T-12 NPs (red) into the vitreous body in ex-
vivo porcine eyes (n=6-8), standard deviation added. For comparison the data for the 
control Atto-488 is also given (blue). Normalization to solution showed a lower 
fluorescence for U4T-12 directly after injection, but higher mean values at all time points 
after 15 min compared to the control dye, indicating efficient long-term retention.  
Normalization to the solution indicated clear differences between the NP and the 
control. Directly after injection the found average intensity for the NPs (19 %) was 
slightly lower than for the Atto-488 solution (22 %). Strikingly, the fluorescence 
intensity of U4T-12 NPs increased from the measurements taken directly after 
injection to 30 minutes after that (22%). In contrast to the control, the NPs were 
detected at higher levels after the first five minutes and for the rest of the duration 
of the experiment.  
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Figure 12 Integrated fluorescence intensity normalized to the instant measurement at 
different time points after injection of the U4T-12 NPs (red) into the vitreous body in ex-
vivo porcine eyes (n=6-8), standard deviation added. For comparison the data for the 
control Atto-488 is also given (blue). U4T-12 displayed higher mean values at all observed 
time points compared to the control dye indicating excellent retention. 
The obtained data was also normalized to the signal determined directly after 
injection (Figure 12). Similar to the observation in Figure 11, the integrated 
fluorescence intensity for the U4T-12 NPs increased after the first measurement 
to a maximum of 121 % after 30 minutes. Relatively consistent fluorescence 
intensity was observed until the two hours measurement (112 %). A sharp 
decrease followed and after 24 hours approximately 20 % of the initial 
fluorescence remained.  
 
Afterwards, the properties of U4T-18 NPs were investigated. Analogous to the 
first studied NP, it was comprised of four modified nucleotides, but contained a 
larger segment of conventional bases. The preparation and analysis were 
undertaken as described in 2.4. First, the fluorescence signal was normalized to 
the solution value (Figure 13).  
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Figure 13 Integrated fluorescence intensity normalized to the solution measurement at 
different time points after injection of the U4T-18 NPs (light blue) into the vitreous body in 
ex-vivo porcine eyes (n=6-8), standard deviation added. For comparison the data for the 
control Atto-488 is also given (blue). When lipid modified DNA-normalized to solution U4T-
18 NPs showed higher mean values at all time points compared to the control dye 
indicating good retention. 
U4T-18 NPs (39 %) started at almost double the percentage of the solution value 
compared to the control (22 %) at the instant time point. Afterwards it decreased 
steadily and in a similar fashion. U4T-18 NPs showed higher levels of 
fluorescence than the control at any given time point and did not drop below the 
10 % mark within the first four hours after injection. 
  
Figure 14 Integrated fluorescence intensity normalized to the instant measurement at 
different time points after injection of the U4T-18 NPs (light blue) into the vitreous body in 
ex-vivo porcine eyes (n=6-8), standard deviation added. For comparison the data for the 
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control Atto-488 is also given (blue). U4T-18 displayed higher mean values at all time 
points after 15 minutes compared to the control dye indicating proper retention properties. 
Also for U4T-18 the obtained data was compared to the instant value that was 
detected directly after injection (Figure 14).The decrease in fluorescence intensity 
found for the U4T-18 solution was constant after the instant time point. The 
measured NP fluorescence stayed below the control the first 30 minutes after 
injection. For all other time points U4T-18 was found to hold higher values than 
the control which dropped to 8 % after eight hours whereas the NPs stayed above 
the 20 % mark. 
 
After evaluating the diffusion properties of two NPs bearing four modified 
deoxyuracils, three NPs containing six modified nucleotides were evaluated. 
First, the fluorescence of U6T-12 NPs was investigated, which contained a total 
of twelve bases of which only 50 % were unmodified. All steps of this process 
were undertaken as described in in 2.4 and initially normalized to the solution 
value (Figure 15). 
 
Figure 15 Integrated fluorescence intensity normalized to the solution measurement at 
different time points after injection of the U6T-12 NPs (orange) into the vitreous body in 
ex-vivo porcine eyes (n=6-7), standard deviation added. For comparison the data for the 
control Atto-488 is also given (blue). Directly after injections the values for U6T-12 NPs 
were slightly lower than the control. Other than that, this NP showed higher mean values 
at all time points, demonstrating good long-term retention. 
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All time points showed a higher fluorescence for U6T-12 than for the control. The 
amount of integrated fluorescence for U6T-12 detected instantly after injection 
was 28% and remained constant until after the five minutes measurement. A 
steady decrease followed and after the eight hours measurement the integrated 
fluorescence dropped below 10 %. 
 
 
Figure 16 Integrated fluorescence intensity normalized to the instant measurement at 
different time points after injection of the U6T-12 NPs (orange) into the vitreous body in 
ex-vivo porcine eyes (n=6-7), standard deviation added. For comparison the data for the 
control Atto-488 is also given (blue). The fluorescence intensity for U6T-12 was higher than 
the initial time point at 5 minutes after injection and slowly decreased afterwards, 
indicating good retention properties. 
Afterwards the fluorescence measurements for U6T-12 were normalized to the 
determined instant value (Figure 15). The fluorescence intensity for the U6T-12 
NPs showed a steady decreasing trend with higher values than the control at any 
given stage. At the instant time point the detected value remained at 97% of the 
instant measurement. U6T-12 stayed at a remarkably high level above 80% of 
integrated fluorescence intensity before it dropped to 69% after one hour. Even 
two hours after injection, the detected intensity remained above 50 % and was 
found at 52 % of integrated instant fluorescence.  
 
The next NP to be investigated was U6T-18. Similar to U4T-18 it consisted of a 
total of 18 nucleotides. However, in this case six were modified with an alkyl 
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chain. The integrated fluorescence intensity was firstly normalized to the solution 
value (Figure 17).  
 
Figure 17 Integrated fluorescence intensity normalized to the solution measurement at 
different time points after injection of the U6T-18 NPs (purple) into the vitreous body in ex-
vivo porcine eyes (n=6), standard deviation added. For comparison the data for the control 
Atto-488 is also given (blue). The fluorescence intensity of U6T-18 NPs higher than the 
control dye at all observed time points and almost reaches solution levels. This suggests 
outstanding retention properties. 
Remarkably, the found fluorescence intensities of U6T-18 NPs are the highest 
ones observed for all solution normalized values of the investigated NPs. The 
integrated fluorescence intensity of 15 minutes (73%) exceeds the one of five 
minutes (67%) but stays below the instant value (80%). This value was the 
highest one found for all NPs. In addition, only the intensity of U6T-18 NPs 
remained decisively over 20 % at the four hour measurement (26%) due to its 
slow decrease. Also, it must be noted that for this NPs the relative intensity 
always stayed above those measured for the control.  
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Figure 18 Integrated fluorescence intensity normalized to the instant measurement at 
different time points after injection of the U6T-18 NPs (purple) into the vitreous body in ex-
vivo porcine eyes (n=6), standard deviation added. For comparison the data for the control 
Atto-488 is also given (blue). The U6T-18 NPs exhibited higher fluorescence at all observed 
time points compared to the control dye, showing good retention. 
As before, the obtained data were also compared to the instant value (Figure 18). 
Also here the integrated fluorescence intensity of 15 minutes (95%) exceeded the 
one of five minutes (88%). Afterwards, the fluorescence intensity decreased in a 
constant manner over time, but always remained at a notably higher level than 
the control. Two hours after injection, the detected intensity remained just under 
50 % of the initial value and was found at 49 %. After four hours it dropped to 33 
%.  
 
The longest and last NP to be investigated was U6T-20, containing a total of 20 
nucleotides of which six were modified with lipid tails. At first, the integrated 
values were normalized to the fluorescence intensity of the solution before 
injecting (Figure 19). 
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Figure 19 Integrated fluorescence intensity normalized to the solution measurement at 
different time points after injection of the U6T-20 NPs (beige) into the vitreous body in ex-
vivo porcine eyes (n=6), standard deviation added. For comparison the data for the control 
Atto-488 is also given (blue). The U6T-20 NPs demonstrated higher fluorescence values at 
all time points when compared to the control dye. This indicates that these NPS possesses 
efficient retention properties. 
Right after injection the amount of U6T-20 (35 %) was notably higher than the 
control (22 %). This NP showed a similar steady decrease to U4T-18 and 
remained at higher levels of fluorescence than the control. U6T-20 did not drop 
below the 10 % mark within the first eight hours after injection.  
 
Figure 20 Integrated fluorescence intensity normalized to the instant measurement at 
different time points after injection of the U6T-20 NPs (beige) into the vitreous body in ex-
vivo porcine eyes (n=6), standard deviation added. For comparison the data for the control 
Atto-488 is also given (blue). The U6T-20 NPs showed a slow decrease of the intensity over 
time compared to the control dye, implying efficient retention properties. 
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Also for the last NP the obtained data was normalized to the instant value (Figure 
20). The measured intensity of U6T-20 decreased constantly over time after 
injection. However, after the five minute time point it had only lost 7 % in 
fluorescence intensity and at 15 minutes it remained at 85 %. While the initial time 
period doubled from hereon (30 minutes, 1, 2, 4 hours) the value of measured 
fluorescence intensity decreased by approximately 10% every time. The 24 hour 
value was the highest one found out of all investigated NPs when normalized to 
the instant time point (17%). 
 
In the fluorophotometric analysis U4T-12 and U6T-18 showed superior 
performance in regard to their diffusion and half life time. First of all, when 
normalized to the instant fluorescence, U4T-12 convinced with high relative 
values, a strong plateau phase and a late decrease in integrated fluorescence. 
Secondly U6T-18 displayed one of the highest levels of intensity and a steady 
decrease over time especially in the solution measurements. These results made 
U4T-12 and U6T-18 suitable candidates for further experiments in an in-vivo 
setup. 
 
3.1.2. Examination of adhesion sites and variations in adhesion duration of 
DNA NPs in an ex-vivo setup 
As a next step in the investigation of the use of DNA NPs for drug delivery to the 
posterior segment the adhesion of these vehicles to ocular tissue has been 
investigated by fluorescence microscopy. Before introducing the results, a good 
understanding of the observed structures in the retina is needed. As outlined in 
the introduction, after DAPI staining the cells can be observed in blue when 
imaging the sections. For visualization the employed NPs were functionalized 
with a green fluorescent dye, similar as described in the previous section. A 
typical example of a NP positive picture after intravitreal injection is given in 
Figure 21. In the figure the different cell layers that are found in the retina are 
named and the NPs are clearly visible in green. This allows analysis of their 
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adhesion sites. As can be seen, the NPs appear as a thin layer of green 
fluorescence on the GCL of the retina. 
 
Figure 21 Fluorescent image of the retina of an ex-vivo porcine eye that has been injected 
with U6T-20 NPs. The designations of the different retinal layers were visualized. Coming 
from the vitreous body and going out of the eye these layers are: ganglion cell layer (GCL), 
inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (ONL), outer 
nuclear layer (OPL), photoreceptor layer (PRL) and the choroid.  
In order to obtain representative pictures for the conditions multiple sections were 
stained for each eye and several selection criteria were used. One of these 
naturally included the overall quality of the section and the integrity of the retina. 
Another important criterion was the inherent fluorescence of the tissue. To gauge 
the extent of autofluorescence of the observed tissue, a third filter was employed. 
As no specific staining was performed with a dye for this filter, any fluorescence 
observed here must have been due to autofluorescence. Samples that exhibited 
a large amount of autofluorescence were omitted in the evaluation. 
First the control dye was injected into the porcine vitreous body in order to prove 
that any observed adhesion of the NPs to the intraocular tissue is due to their 
structure. Therefore pig eyes were injected with 40 µL of 20 µM Atto-488 solution. 
After defined incubation times of 5, 15, 30 minutes, 1 and 2 hours in PBS they 
were prepared as cryosections and stained with DAPI. The sections were then 
investigated under the fluorescence microscope (Figure 22). 
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Figure 22 Representative fluorescent images of retinas of ex-vivo porcine eyes after 
injection with the Atto-488 control and incubation for designated time points. No signs of 
fluorescence were observed. Bottom right: table with number of control positive eyes at 
different time points, confirming the absence of the control dye. 
As expected, the eyes injected with the control did not show any positive results 
regarding adhesion of the fluorescent dye towards the retinal tissue in any of the 
analyzed time points. Also, in no other tissues or the vitreous body itself 
fluorescence was found in any of the cryosections. Hence, it can be concluded 
that the small molecular dye did not exhibit any affinity to the retinal tissue.  
Time points Positive results
5 min 0/3
15 min 0/3
30 min 0/3
1 h 0/3
2 h 0/3
5 min
30 min 1 h
2 h
15 min 130 µm
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In the next step to investigate the affinity of the NPs to ocular structures, the same 
experiment was performed with different NP vehicles. First, U4T-12 was injected 
in ex-vivo porcine eyes as explained in 2.4.4 and the adhesion was analyzed by 
fluorescence imaging (Figure 23).  
 
Figure 23 Representative fluorescent images of retina of ex-vivo porcine eyes, injected 
with U4T-12 NPs and incubated for designated time points. Bottom right: table with number 
of control positive eyes at different time points. The amounts of displayed NPs in the 
pictures and the results from the table indicated excellent adhesion towards the retinal 
tissues. 
Time points Positive results
5 min 3/3
15 min 3/3
30 min 2/3
1 h 3/3
2 h 3/3
5 min
30 min 1 h
2 h
15 min 130 µm
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The U4T-12 NPs can clearly be identified as their green fluorescence is highly 
visible in the obtained images. The NPs formed a considerable layer on the inner 
parts of the retina, mainly on the inside of the GCL, on the border to the vitreous 
body. At five minutes post injection, NPs could already be observed in the cellular 
structures. The green fluorescence was mainly found surrounding the DAPI 
stained nuclei on those cells which were facing towards the vitreous body. The 
total depth of the layer of NPs found in the vitreous was approximately 300 
micrometer (µm). Strikingly, NPs could be observed that were not directly bound 
to the cells, but rather located in the vitreous body itself. This has not been the 
case for the control dye. Also, the NPs were fully covering the retina displayed on 
this picture with the most pronounced adhesion site in the region of the outer GCL 
nuclei.  
For later time points a more distinct line of the fluorescent NPs was visible with a 
dense pattern of the NPs located at the GCL. Additionally, at the later time points 
the green fluorescence was found in more basal parts of the retina. This was very 
well visible at one and two hours post injection. For example, at the two hours’ 
time point high coverage of the retina was found with an average penetration 
depth of the NP layer of around 120 µm. It was obvious that the NPs reached 
below the GCL and had contact with the INL.   
In almost all investigated eyes the NPs were found to adhere to the cellular layers 
of the retina. Only one eye was found 30 minutes after injection where the NPs 
were not detected. However, later time points again showed good adhesion to 
the retinal structures again. 
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Figure 24 Representative fluorescent images of retina of ex-vivo porcine eyes, injected 
with U4T-18 NPs and incubated for designated time points. Bottom right: table with number 
of control positive eyes at different time points. The clearly visible NPs in the pictures and 
the results from the table indicated good adhesion towards the different tissues in the 
retina. 
Similar to the fluorophotometric study, the U4T-18 NPs were injected next (Figure 
24). U4T-18 covered the entire width of the retina shown in the five minutes 
micrograph. However, the fluorescence observed was not as strong as found for 
U4T-12 and mainly formed by multiple spots. These were connected by smaller 
lines of NPs adhesion to the retina that penetrated less than 30 µm deep. With 
Time points Positive results
5 min 2/3
15 min 3/3
30 min 2/3
1 h 2/3
2 h 3/3
5 min
30 min 1 h
2 h
15 min 130 µm
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longer incubation periods, the presence of the NPs appeared to migrate from 
around the GCL to the more basal structures. Strikingly, the layer of fluorescence 
formed broad lateral borders in the two hours picture. However, compared to the 
U4T-12 NPs, these vehicles displayed a fainter fluorescence. Also, the mean 
depth of the found green stratum seemed lower than for the first investigated NP.  
At three out of five time points 2/3 injected eyes were NP positive. The time points 
of two hours and 15 minutes displayed the only 100% positive findings which 
were two less than in the U4T-12 analysis. This underlined the trend observed in 
the images, regarding the characteristics of the found fluorescence. 
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Figure 25 Representative fluorescent images of retina of ex-vivo porcine eyes, injected 
with U6T-12 NPs and incubated for designated time points. Bottom right: table with number 
of control positive eyes at different time points. The observed NPs in the pictures 
combined with the positive results from the table showed the outstanding adhesion of this 
NP towards the retinal tissues. 
As first NP with six modified nucleotides, U6T-12 was investigated (Figure 25). 
The injected U6T-12 NPs demonstrated positive findings in all given time points 
that were investigated. They were especially located in the GCL, a characteristic 
which has been observed also for the previous NPs. However, in contrast to the 
previous NPs, U6T-12 showed less intense fluorescence and also covered less 
Time points Positive results
5 min 2/3
15 min 2/3
30 min 3/3
1 h 3/3
2 h 3/3
5 min
30 min 1 h
2 h
15 min 130 µm
Results 
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area. For example, in the 5 minutes image only one location with NPs could be 
identified that exhibited a high local intensity and a diameter of approximately 
100 µm. After 15 minutes of incubation the green fluorescing NPs covered the 
entire inside of the GCL but the lining was not as intense as for the earlier 
investigated NPs and below 100 µm in depth. Unlike those early time points, the 
ones from 30 minutes and onwards showed stronger fluorescence intensities 
over almost the entire GCL. After 30 minutes of incubation, six sites of NPs 
partially covered the GCL, which displayed local gaps. Those aggregations had  
a maximum diameter of 130 µm. After one hour the NPs were covering 
approximately 50 % of the retina and were also localized in the vitreous body. 
Despite forming a ribbon shaped pattern throughout the picture, the NPs were 
still locally stronger concentrated and did not distribute evenly over the retina. 
After two hours of incubation the ribbon like structures were not apparent but the 
NP covering on the GCL was distinct and to be found on the entire inside of the 
GCL. In summary, U6T-12 showed rather weak fluorescence with incomplete 
coverings in the majority of the given images. A total of 13/15 positive results 
were found whereas for the incubation times of 5 and 15 minutes only 2/3 eyes 
were positive. 
Similar as for the NPs U4T-12 and U4T-18, also NPs having six lipid-modified 
bases and more conventional nucleotides were investigated. Therefore, first U6T-
18 was analyzed in regard to adherence towards the retinal tissues (Figure 26). 
It should be mentioned here that for the fluorophotometric results, the U6T-18 
NPs showed promising results regarding their retention in the vitreous body. 
Preparation and injection were undertaken as described in 2.4.4. 
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Figure 26 Representative fluorescent images of retina of ex-vivo porcine eyes, injected 
with U6T-18 NPs and incubated for designated time points. Bottom right: table with number 
of control positive eyes at different time points. The amounts of displayed NPs in the 
images and the results from the table indicated excellent adhesion towards the tissues of 
the retina. 
In the U6T-18 series the fluorescently labelled NPs were found covering the retina 
throughout the incubation time points with predominant adherence on the inside 
of the GCL. Already five minutes after injection the fluorescent NPs were covering 
the entire GCL, albeit with a lower intensity than found for the U6T-12 NPs. In 
contrast, no gaps were observed. In the 15 minutes image the NPs were found 
Time points Positive results
5 min 2/3
15 min 3/3
30 min 3/3
1 h 3/3
2 h 3/3
5 min
30 min 1 h
2 h
15 min 130 µm
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as multiple spots sized below 80 µm in diameter but displaying a strong intensity. 
The significant difference to previously investigated NPs was the presence of NP 
fluorescence in the vitreous body, even after longer incubation periods. In the 30 
minutes picture the NPs present in the vitreous appeared as of weak intensity 
with two highly intense but local accumulations of less than 100 µm in the GCL. 
After one hour of incubation the coating was much more intensive with an 
average depth of 80 µm and covering approximately 90 % of the retina. In the 
last time point of this series the retention properties of U6T-18 became 
particularly obvious. The imaged fluorescence formed an accumulation which ran 
in strings through the network of the vitreous and measured over 200 µm. The 
GCL was coated in a distinct line of NPs over its entire width. Recapitulating the 
findings for U6T-18 one must note the predominance of NP which was still to be 
found in the vitreous body after two hours, stressing the retention qualities of this 
NP. However, U6T-18 also formed a constant coating displaying rather intense 
fluorescence on the GCL and therefore appeared more favorable in regard to 
adherence properties than for example U4T-18 or U6T-12 NPs.  
These findings are also in good agreement with the observed results found in the 
fluorophotometric measurements. Additionally, the summarizing table underlined 
this with 14/15 eyes found to be positive. This was the same amount of positive 
results that had also been found for the U4T-12 NPs.  
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Figure 27 Representative fluorescent images of retina of ex-vivo porcine eyes, injected 
with U6T-20 NPs and incubated for designated time points. Bottom right: table with number 
of control positive eyes at different time points. The NPs in the pictures and the results 
from the table indicated effective adhesion towards the retina. 
The U6T-20 NPs were last investigated for adherence and distribution in the 
ocular tissue. Porcine eyes were prepared and injected as described in 2.4.4. 
For U6T-20, fluorescence was found in all given time points but in lower intensity 
compared to previously investigated NPs. After five minutes just three fluorescent 
spots could be identified in the GCL. After 15 minutes the fluorescence became 
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2 h 3/3
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stronger but was mainly found as a single spot of approximately 130 µm 
diameters. At 30 minutes of incubation the fluorescence began to form a uniform 
layer on the inside of the GCL, but exhibited a faint fluorescence compared to 
previously found results. In contrast, the one hour result displayed a much 
stronger and dense coating, which was not comparable to the other findings for 
U6T-20. Here, the entire GCL was covered by a green stratum of NPs. In the last 
image of the series the fluorescence was concentrated at four locations with a 
width and depth below 100 µm. In comparison to the fluorescence find after one 
hour, the figure at two hours suggested a lower covering of the GCL. In summary, 
this last NP appeared less promising than the previously investigated NPs. This 
was primarily due to weak intensity of fluorescence and non-existent coverage in 
the majority of the eyes.  
The table supported what has been observed in the images. With only 12/15 the 
positive findings in the eyes injected with U6T-20 were as frequent as in the ones 
injected with U4T-18 solution. Strikingly, the early time points (5, 15 and 30 
minutes) lacked positive results. Those were also the ones where the 
fluorescence in the images appeared weaker. 
 
The fluorescence imaging of U4T-12 and U6T-18 showed excellent coverage of 
NPs in regard to the retinal tissue. Both were found to be the only NPs out of this 
ex-vivo setup displaying 14/15 positive eyes. Indicating superior performance, 
U4T-12 and U6T-18 NPs have been chosen for further in-vivo experiments. 
 
3.2. Intravitreal injection of lipid-modified DNA NPs into in-vivo 
rat eyes 
After exploring the diffusion through the vitreous body and the adhesion potential 
of the DNA-NPs, in-vivo injections were administered using the two best 
performing NPs selected from the ex-vivo investigations. To this extent one NP 
from the group containing four lipid modified nucleotides and one from the group 
containing six lipid modified nucleotides were selected. Here U4T-12 and U6T-
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18 were chosen due to their prolonged retention after injection and excellent 
adhesion to the ocular structures. The in-vivo experiments were performed by 
injecting the NPs in rat eyes. Again, the free Atto-488 served as control. Similar 
to the ex-vivo part, the retention and adhesion was first investigated by ocular 
fluorophotometry and afterwards through fluorescence microscopy. 
3.2.1. Examination of diffusion of DNA NPs within an in-vivo vitreous body 
In order to analyze the diffusion behavior of the NPs the in-vivo rat eyes were 
scanned using a fluorophotometer. However, unlike previously performed, the 
graphs were not integrated. This because the in-vivo rat eye model made the 
implementation of a constant measurement axis over several days impossible. 
As a result, no reliable data could be obtained from a single animal over several 
days. Therefore it was decided to select representative scans of the injected Atto-
488 control solution, U4T-12 and U6T-18 NPS in order to highlight the different 
diffusion manners of the control solution versus NPs.  
The graph presented in Figure 28 gives an indication of the diffusion of the small 
molecular control in the vitreous and aqueous humor of the rat eye. The 
autofluorescence observed in the eye is illustrated by the “pre injection” graph 
which was obtained directly before injection. Several characteristic local peaks 
could be found which indicate the position of the retina and the cornea. For 
orientation purposes the approximate position of retina and cornea were 
highlighted in the figure. A smaller peak can be found between these two which 
may be observed due to auto fluorescence in the area of iris and lens.  
Results 
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Figure 28 Fluorescence intensity (y axis) measured at different time points after intravitreal 
injection of Atto-488 along the optical axis (x axis) in an in-vivo rat eye. The fast decrease 
in intensity over time indicated rapid diffusion of the dye into the vitreous body.  
As expected, a strong peak was detected right after injection of the control 
solution. The position of this peak indicated the location of the maximum 
concentration of the dye inside the vitreous. All the following measurements did 
not differ discernible from the pre injection measurement, indicating rapid 
clearance of the control dye out of the optical axis of the eye. This was also in 
good agreement with the results observed earlier in the ex-vivo experiments. 
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Figure 29 Fluorescence intensity (y axis) measured at different time points after intravitreal 
injection of U4T-12 NPs along the optical axis (x axis) in an in-vivo rat eye. The stark 
decrease in intensity on the first day can presumably be explained by difficulties in 
aligning the measured eye with the fluorophotometer. 
Next the diffusion characteristics for the intravitreally injected U4T-12 NPs are 
investigated) (Figure 29). Compared to the detected fluorescence found for Atto-
488, the displayed figure indicated approximately one fifth of the intensity for the 
U4T-12 “0 days” measurement. This lower value can be explained by the 
conjugation of the dye to the complementary DNA, as was described in section 
3.1.1. The position of the peak was similar to the one previously observed for the 
control in the vitreous. However, measurements for the later time points did not 
display any positive peaks exceeding the levels of fluorescence found in the eye 
before injection. This finding was most likely due to changes in positioning of the 
eye between measurements and hence related to problems in aligning the optical 
axis of the eye to the optical axis of the fluorophorometer. 
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Figure 30 Fluorescence intensity (y axis) measured at different time points after intravitreal 
injection of U6T-18 NPs along the optical axis (x axis) in an in-vivo rat eye. A drop in the 
intensity over time was observed, which stressed the retention properties of the NPs. 
In Figure 30 the diffusion characteristics for the intravitreally injected U6T-18 NP 
are presented. As can be seen in the figure above, the detected fluorescence 
right after injection of the U6T-18 showed a different profile both in height and 
shape of the peak when compared to the control. The found fluorescence 
intensity was less than half the amount of Atto-488, which again could be 
attributed to the conjugation of the dye to the complementary DNA. Secondly the 
main peak exhibited shoulder peaks on both sides. Nevertheless, the location of 
the peak was the same as the “0 days” peak found for Atto-488. Remarkably, one 
day after injection the peak had changed position and intensity. The peak height 
was half of the original amount and it had relocated more towards the retina. After 
three days a slightly higher fluorescence was found than before injection. Here 
the observed peak had shifted slightly towards the cornea. This observation 
presumably was due to aligning problems of the rat eye with the measured optical 
axis. Finally, five days after injection no difference to the initial state could be 
detected.  
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After confirming the prolonged presence of at least one of the NPs in the 
intraocular space, their adherence to the ocular structures was investigated by 
fluorescence microscopy.  
3.2.2. Examination of adhesion sites and variations in adhesion duration of 
DNA NPs in an in-vivo setup 
In a similar fashion as in the ex-vivo experiments, the control was first 
investigated. Rats were injected with 10 µL of the Atto-488 control (20 µM) into 
the vitreous. The rats were sacrificed after ½, 1, 3 or 5 days. The eyes were 
enucleated, frozen and prepared as cryosections before performing nucleus 
staining with DAPI. Fluorescence imaging was used in order to define the 
adhesion sites and the presence of the control (Figure 31).  
Results 
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Figure 31 Representative fluorescent images of the retina of rat eyes injected with Atto-
488 at different time points. Bottom: table of positive results found in the eyes at different 
time points. In agreement with earlier experiments, no adhesion of Atto-488 towards the 
retina was found. 
As expected, the eyes injected with the control were found to be negative in all 
investigated time points regarding the adhesion of the fluorescent dye towards 
the retinal tissue (Figure 31). Also no fluorescence was found in the vitreous body 
of any the analyzed eyes or in any of the prepared cryosections. It can be 
concluded that the small molecular dye did not exhibit any affinity to the retinal 
tissue, as was already observed in the ex-vivo experiments.  
After confirming that the control dye did not exhibit any affinity to the ocular 
structures, the adhesion behavior of the lipid-modified DNA NPs could be 
Time points (d) Positive results
½ 0/6
1 0/6
3 0/6
5 0/6
½ d
3 d 5 d
130 µm1 d
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investigated. First U4T-12 NPs were injected by administration of 10 µL of 20 µM 
solution into the vitreous body. Afterwards the rats were sacrificed at the same 
defined time points and processed as described previously (Figure 32). 
 
Figure 32 Representative fluorescent images of the retina of rat eyes injected with U4T-12 
at different time points. Bottom: table of positive results found in the eyes at different time 
points. The pictures and the table displayed excellent adhesion of U4T-12 towards the 
retinal tissues and their retention in this matrix. 
Already half a day after injection the U4T-12 NPs showed a strong presence in 
the vitreous and exhibited a thick layer of NP on the inside of the retina. The 
fluorescent NPs in the vitreous body showed filamentous arrangements, which 
represented the network structure of the vitreous. The fluorescing stratum on the 
retina itself was mainly located around the nuclei of the entire GCL, measuring 
Time points (d) Positive results
½ 5/6
1 4/6
3 3/6
5 1/6
½ d
3 d 5 d
130 µm1 d
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approximately 100 µm in dept. At one day post injection, the NPs were mostly 
located 50 µm inside from the retina in the vitreous body. However, no layer of 
fluorescence was found in the GCL. Instead, the NPs formed a reticular structure 
exhibiting a high fluorescence, indicating high local concentrations. At the widest 
location it measured approximately 200 µm in depth. Also, in the majority of the 
intravitreal space the presence of NPs could be observed. In the picture taken 
three days after NP application the injection site could be seen. At this location a 
couple of cells had been dislocated into the vitreous and the injection canal was 
partially still observable. Noticeably the majority of the pictured fluorescence was 
to be found outside the ONL approximately at the position of the injection site. A 
depot of NPs of approximately 300 µm wide and 130 µm deep had accumulated 
here. Signs of fluorescing NPs were stretching out into the INL, characterized by 
a dense layer of nuclei. The fluorescence findings at this three days’ time point 
were not as area-wide as the ones before. Additionally, they were limited to the 
site of injection and no NPs were found in the GCL. In the five days image, a 
number of cells were observed in the vitreous, about 200 µm from the retina. 
They were surrounded by fine isolated fibers of NP. Outside of this location no 
presence of NPs was obvious. The enveloped fluorescing molecules appeared 
to form a thin layer on the surfaces of the cells.  
In summary, half a day after injection the NPs formed an intensive coating with 
an average depth of 100 µm on the inside of the retina. After one day however 
no coating was present but filamentous structures formed an aggregate of locally 
200 µm in diameter just outside of the retinal tissue in the vitreous body stretching 
over 2/3 of the displayed width. Afterwards, NPs were only displayed outside the 
ONL at the injection site (three days) or encapsulated by dislocated cells in the 
vitreous (five days). The table underlined the tendency already indicated by the 
pictures. After half a day 5/6 rat eyes showed positive findings. After day one only 
4/6 could be identified as positive. After three days this decreased to only half of 
the analyzed samples showed presence of fluorescence and only 1/6 eyes was 
showing NPs under the fluorescence microscope five days post injection.  
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Figure 33 Representative fluorescent images of the retina of rat eyes injected with U6T-18 
at different time points. Bottom: table of positive results found in the eyes at different time 
points. The pictures and the table exemplify the outstanding adhesion and retention of 
U6T-18 towards the retinal tissues. 
With six modified bases, U6T-18 was the second NP investigated in an in-vivo 
setup (Figure 33). The experiment was performed as described for U4T-12. 
The U6T-18 NPs showed a lot of similarities in the half day time point to the one 
of U4T-12. The filamentous arrangements in the vitreous appeared to be fainter 
but were also arranged in a reticular pattern. The faint formation surrounding 
these filaments was less bright in this picture, but still visible. The most 
remarkable difference was the NP stratum on the GCL, which was nowhere near 
as strong as for U4T-12. A couple of green spots indicated the presence of NPs 
Time points (d) Positive results
½ 5/6
1 4/6
3 4/6
5 1/6
½ d
3 d 5 d
130 µm1 d
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between the GCL and the INL. Here, fluorescence was present in the inward 
tissue from the retina on in the entire width of the displayed picture. The image 
obtained after one day showed a definable line of NP originating from the retina 
and continuing inwards into the vitreous body. However, no extensive diffusion 
from the vitreous toward the retina was visible. On the left side of the picture the 
NPs made contact with the retina in the GCL. At three days after injection, a line 
of NPs could be detected similar in appearance to the previous time point and 
measuring around 500 µm in length. The fluorescing NPs were less prominent 
than before and attached to dislocated cells in the vitreous. These cells were 
presumably disrupted due to the injection. Remarkably, in the image of five days, 
a thin layer of NPs was again established, covering approximately 1/3 of the 
displayed retina. The NPs were located towards the inside of the eye on the GCL. 
Local spots of comparatively strong fluorescence, but mostly less than 10 µm 
diameter were mainly in line with the described covering of NPs. One noticeable 
aggregation of NPs of 200 µm in the center of the image represented the thickest 
part of the observed stratum. Faint reticular filaments were visible in the upper 
left quadrant, similar to those displayed in the pictures of the early time points. 
All in all U6T-18 displayed a consistent location of NPs in the GCL with dominant 
presence of filamentous structures of NPs in the vitreous for the half day time 
point. The one and three day images showed a definable line of green NPs 
spreading out parallel to the retina with mostly no contact to the different retinal 
layers. Remarkably, in the image of five days a covering was again visible, 
stretching out approximately over 1/3 of the displayed retina, incorporating spots 
of strong fluorescence of approximately 10 µm in size.  
A declining trend in occurrence of positive findings was obvious (Figure 33). U6T-
18 NPs were detected in 5/6 eyes after half a day and 4/6 positive after one and 
three days. Only 1/6 eyes was found to be positive five days after injection. 
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3.3. Injection of lipid-modified DNA NPs into periocular tissue 
of in-vivo rat eyes 
3.3.1. Examination of adhesion sites and variations in adhesion duration of 
DNA NPs in an in-vivo setup 
After proving the retention in the vitreous and adhesion potential of the lipid-DNA 
NPs after intravitreal injection in ex-vivo and in-vivo models, further experiments 
were undertaken to evaluate other possible administration sites for the treatment 
of retinal diseases. One promising approach was the injection of drugs into the 
periocular tissue. From here the medication could then diffuse into the ocular 
space to reach clinically relevant concentrations at the retinal tissue. In the 
previous section the different layers of the retina were already introduced. In the 
following the tissue outside the bulbus is going to be focused upon.  
Because of the positive results obtained after intravitreal injection, the retention 
of the NPs in the periocular tissue was directly studied in-vivo using fluorescence 
microscopy. A typical example of microscopy imaging after periocular NP 
injection is given in Figure 34. After DAPI staining the typical layer-structure of 
the retina, choroid, sclera and connective tissue becomes visible and their 
location has been indicated as before. Additionally, the sclera and the connective 
tissue were labelled. The NPs that were applied using a subconjunctival injection 
route appear as green fluorescent moieties adhering towards the outside of the 
sclera and between the cells of the connective tissue.  
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Figure 34 Fluorescent image of a rat eye 24 hours after in-vivo periocular injection of U4T-
12 NPs showing the retina, sclera and connective tissue. Designation of different layers is 
displayed. Coming from the vitreous body and going out of the eye the found layers are: 
ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer 
plexiform layer (ONL), outer nuclear layer (OPL), photoreceptor layer (PRL), choroid, sclera 
and the connective tissue.  
From the intravitreal injection of the two selected NPs, U4T-12 has been identified 
as having the strongest adherence towards the ocular structures. Therefore this 
NP was selected for initial studies using subconjunctival injections. In this 
experiment the retention in the surrounding tissue was compared to the small 
molecular control Atto-488 and time points of 30 minutes, two hours and four 
hours were selected. Although these periods were significantly shorter than those 
chosen for intravitreal injection, they were selected to obtain preliminary 
information about the retention of U4T-12 in the periocular space. To this end rats 
were injected with 40 µL of 20 µM NP solution into the subconjunctival tissue. 
The animals were sacrificed after the designated time and the eyes including the 
surrounding tissue were enucleated, frozen and prepared as cryosections. 
Counterstaining with DAPI was performed and the presence of the fluorescently 
labelled NPs was studied by fluorescence microscopy (Figure 35).  
ONL
INL
GCL
Choroid
OPL
IPL
130 µm
PRL
Sclera
Connective-
tissue
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Figure 35 Representative fluorescent images of rat eyes after periocular in-vivo injection 
of U4T-12 NPs (left column) or Atto-488 control (right column). Visible are the retina, sclera 
and surrounding periocular connective tissue at different time points post injection. 
Below: table of time points and positive eyes found injected with the respective solutions. 
In stark contrast to the control dye, the animals treated with U4T-12 displayed a large 
amount of the NPs at a high intensity. 
Time 
points
Positive
U4T-12
Positive 
Atto-488
30 min 2/2 0/2
2 h 2/2 0/2
4 h 2/2 0/2
30 min
2 h
4 h
130 µmU4T-12 Atto-488
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Already 30 minutes after subconjunctival application of Atto-488, the control did 
not provide any positive results regarding its adhesion towards the connective 
tissue outside the sclera. Also no other fluorescence was found throughout the 
cryosections of the samples which were injected with the control.  
In stark contrast, the animals treated with U4T-12 displayed a large amount of 
the NPs at a high intensity. For all time points a similar distribution of the 
fluorescent NPs was apparent. The U4T-12 particles were mainly localized on 
the outside of the sclera and form a thick layer covering the complete scleral 
tissue. At 30 minutes post injection the stratum had a rather consistent thickness 
of ca. 100 µm. In contrast, the two later time points varied more in their average 
thickness. The two hours picture showed the same tissue covered but exhibited 
less intense fluorescence. Also, the NP stratum on the outside of the sclera was 
only about half compared to the 30 minutes time point. A similar observation could 
be made for the four hours time point, displaying a layer of approximately 40 µm 
thickness on the scleral surface. In all given pictures for U4T-12 fluorescence was 
spread in a honeycomb-like structure in the connective tissue. No explicit findings 
of fluorescence inside the sclera were apparent although the scleral tissue itself 
seemed to be infiltrated by the NPs, especially in the 30 minutes image. It must 
be noted here that this showed that the U4T-12 carrier did not cross the sclera 
and could therefore not be found in the inner tissues of the eye.  
All six of the eyes injected with U4T-12 were found to be positive, showing strong 
and area wide green fluorescence. This supported the efficacy of the 
subconjunctival pathway, encouraging further experiments. 
The high fluorescence intensity for these shorter time points indicated that the 
diffusion of the NPs was happening at a large time scale, which invited to perform 
the same studies with longer post injection periods. Therefore, U4T-12 and U6T-
18 NPs were injected into conjunctival tissue and their adherence was evaluated 
after one and three days. For the fluorescent control only the one day time point 
was implemented, since all control injections so far had been negative. A 
representative picture for the control experiment is displayed in Figure 36. 
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Figure 36 Representative fluorescent image of rat eyes after in-vivo periocular injection of 
Atto-488 at 1 day post injection.  
As has been seen before in the ex vivo setups, also here the Atto-488 showed 
no sign of retention in the tissue of the injected eyes. Afterwards, both the U4T-
12 and U6T-18 NPs were injected in the periocular tissue. Representative images 
for the given time points are found in Figure 37. 
1 d 130 µm
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Figure 37 Representative fluorescent images of rat eyes after in-vivo periocular injection 
of U4T-12 (left column) or U6T-18 (right column) NPs. Visible are the retina, sclera and 
surrounding periocular connective tissue at different time points post injection. Below: 
table of time points and positive eyes found injected with the respective solutions. Both 
U4T-12 and U6T-18 displayed efficient NP retention at the injection sites up to 3 days post 
injection. 
At one day after injection in the periocular tissue the U4T-12 NPs were found as 
strong green fluorescence on the outside sclera and the connective tissue. The 
NP layer on the ocular surface displayed a continuous stratum throughout the 
tissue with a maximum thickness of approximately 10 µm. Accumulations of NPs 
could be found on the right and on the left side of the picture. The stronger, left 
one measured about 300 µm in width and 100 µm in thickness presenting 
intensive fluorescence. These results were similar to the findings made in the 
shorter observation periods albeit with weaker fluorescence. The correlating U6T-
Time 
points
Positive
U4T-12
Positive 
U6T-18
Positive 
Atto-488
1 d 5/6 5/6 0/2
3 d 6/6 5/6 -
1 d
3 d
130 µmU4T-12 U6T-18
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18 one day image showed a less strong adherence of this specific NP. The NPs 
outside the sclera appeared faint and diffuse but were recognizable nevertheless. 
Due to the blurring boundaries measures could not be given. Additionally, dozens 
of smaller fluorescent spots were observed on the outside of the conjunctive 
subconjunctival tissue. The isolated sections appeared to be randomly spread 
between the cells. After three days the displayed fluorescence for both NPs 
looked very alike. No continuous layer of NPs was visible. For both images the 
green fluorescence only covered half of the pictured scleral surface with the 
fluorescent layers showing less than 10 µm in thickness. Only very hazy and faint 
areas of NPs without distinct spots of fluorescence were obvious.  
In summary, the visible fluorescence decreased in strength and spatial 
distribution with longer time periods. For one day the images for both NPs 
presented near full coverage with strong local accumulation of fluorescence, 
especially for U4T-12 NPs. After three days of incubation the NP stratum only 
covered half of the pictured scleral surface with the fluorescent layers showing 
less than 10 µm in thickness. Nevertheless, one day of incubation for U4T-12 and 
both of the U6T-18 time points displayed 5/6 eyes to be positive. For U4T-12 
even 6/6 eyes were detected with NPs in the subconjunctival tissue at three days 
post injection. However, for neither of the two NPs signs of fluorescence were 
found inside of the bulbus at any of the given time points. 
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4. Discussion 
4.1. Intravitreal injection of lipid-modified DNA NPs into ex-vivo 
pig eyes 
After presenting the evaluation of the performed experiments for NPs as a drug 
delivery platform in section 3, the diffusion behavior, retention in the vitreous body 
and adherence to tissue will be discussed and possible explanations for the found 
observations will be pointed out in the following discussion. 
4.1.1. Examination of diffusion of DNA NPs within an ex-vivo vitreous body 
To illustrate and highlight the differences in diffusion characteristics for the 
investigated NPs, the integrals obtained from section 3.1.1 were merged into a 
single graph. As before, the fluorescence intensity for each time point and every 
NP was first normalized to the solution value (Figure 38).  
 
Figure 38 Integrated fluorescence intensity normalized to the solution measurement (y 
axis) at the different time points after injection (x axis) into the vitreous body for all 
investigated NPs in ex-vivo procine eyes (n=6-8), standard deviation added. In this case 
the U6T-18 NPs were particularly visible as they showed superior properties in regard to 
retention in the vitreous  
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The graph containing the combined integrals clearly highlights the differences in 
decrease of fluorescence intensities for the specific NPs, similar to what was 
already observed in the results section.  
The first clear observation was that all of the NPs exhibited a sudden drop from 
solution to the instant measurements, which could presumably be explained by 
the dilution of the respective NP or control by the vitreous fluid. At this point all 
showed integrated fluorescence intensities lower than 50 % of the initial value, 
with the exception of U6T-18 which was found at 80 %, indicating that it diluted 
not as quickly within the vitreous fluid as the other NPs. Here, U4T-12 showed a 
lower percentage at the instant time point than the control which was detected to 
be at 22 %. After five minutes U4T-12 rose above the control value (19%) to 21 
%. The NP showing remarkable performance in this figure is U6T-18. It had by 
far the highest fluorescence levels until eight hours after injection and displayed 
a steady decrease. After one hour of incubation the investigated U6T-18 level 
remained at approximately 46%, which was more than double of what the closest 
detected fluorescence for the other NPs displayed (21% for U4T-12, U4T-18 and 
U6T-20). 
In the statistical analysis of the values normalized to “solution” U6T-18 exhibited 
a P value of ≤ 0.001 at all given time points. U4T-18 displayed significant values 
at the instant time point and 30 minutes after injection (P ≤ 0.05), as well as after 
1, 2, 4 and 24 hours (P ≤ 0.01) and the highest P value after the eight hours 
measurement (P ≤ 0.001). U6T-20 showed significant values at 15 and 30 
minutes (P ≤ 0.05), 1 and 2 hours (P ≤ 0.01); as well as 4, 8 and 24 hours (P ≤ 
0.001) after injection. U4T-12 displayed a significant value at 30 minutes (P ≤ 
0.05), 1 and 8 hours (P ≤ 0.01) and also 2 and 4 hours (P ≤ 0.001) after injection. 
The NP with the lowest level of significance was U6T-12 with P ≤ 0.05 at 30 
minutes, 1, 4 and 8 hours. 
Analyzing the NPs normalized to their respective solution value provided 
information about the detected fraction of NPs out of the total amount that was 
injected. Additionally, another normalization method was desirable where more 
focus rested on what the diffusion, distribution and retention of the NPs was like 
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after injection. Therefore, in the second method, the fluorescence of each NP has 
been incorporated and normalization to the respective instant measurement of 
the NP was performed.  
The normalization of the measurements to the integrated fluorescence intensity 
right after injection (instant) was incorporated in Figure 39. 
   
Figure 39 Integrated fluorescence intensity normalized to the instant measurement (y axis) 
at the different time points after injection (x axis) into the vitreous body for all investigated 
NPs in ex-vivo procine eyes (n=6-8), standard deviation added. Especially U4T-12 NPs 
displayed outstanding properties concerning their retention in the vitreous body. 
Out of the investigated NPs only U4T-12 exhibited increased fluorescence 
intensity after the instant value, and had its maximum at 30 minutes after 
injection. This would have indicated a further increase in the amount of NP 
present in the vitreous body. As no further injections were applied, this cannot 
have been the case. However, there are several possible explanations for this 
observation which mainly relate to the optical axis of the measurements and the 
diffusion of NPs into it. For administration of the NPs, injections were performed 
at the limbus of the eye. Therefore, the ocular layers were penetrated and the NP 
solution was injected in the approximate center of the vitreous body. However, 
due to the anatomical structure of the vitreous, defined by a framework of 
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collagen fibers, an insertion channel might have remained after drawing back the 
needle. This could have offered an ideal opportunity for the NP to flow back out 
of the injection site and into the preformed channel. However, the 
fluorophotometer only has a limited optical axis in which the NPs are detectable. 
Therefore, directly after injection the detected signal would have been lower than 
it should have been. In the course of the experiment the NPs might have diffused 
back into the optical axis of the fluorophotometer and the measured fluorescence 
could have increased thereafter. The process described above might have 
resulted in a fluorescence maximum being later observed than instantly after 
injection. A second possible reason for the found increase is that injections could 
have been performed slightly outside the optical axis of the fluorophotometer. For 
measurement of the complete amount of injected NP, they would have first had 
to diffuse into the investigated tissues. This might have led to an increased 
fluorescent signal in the first measurements. Lastly, the observed phenomenon 
could also have been a combination of both explanations given above.  
In contrast to U4T-12 which exhibited increasing fluorescence over the first 30 
minutes, all other NPs showed a decreasing trend directly after injection. 
Strikingly, only U4T-18 displayed values below the ones of the control, five (78%) 
and 15 minutes (64%) after injection. Afterwards slower diffusion was observed, 
resulting in an integral that exceeded the Atto-488 value for the later time points. 
Nevertheless, when compared to the other NPs, U4T-18 exhibited the lowest 
average intensities over the course of the experiment.  
The U6T-20 NPs showed a constant decrease in measured fluorescence 
intensity directly after injection and showed a similar profile as U6T-12 and U6T-
18 NPs. It must be noted that already five minutes post injection the three NPs 
exhibited comparable values. At four hours, more pronounced differences were 
evident between the three vehicles. U6T-20 continued the steady decreasing 
trend found in earlier measurements, whereas the U6T-12 and U6T-18 
fluorescence integrals suddenly dropped to only 35% and 35% of their original 
values. Therefore U6T-20 showed the second highest value of all NPs at four 
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hours post injection (42 %). With an observed value of 17 % it eventually became 
one of the two most abundantly present NPs after 24 hours incubation. 
The NP showing the highest fluorescence at all time points was  
U4T-12. It was the only NP that did not drop below its initially measured value 
until the four hours measurement. With that it stayed by far on the highest level 
amongst all NPs until the 24 hours measurement where it was second best with 
approximately 16 % of fluorescence remaining.  
In the statistical analysis for instant normalization U4T-12 was the only NP 
displaying significance before four hours of measurement: 15 minutes (P ≤ 0.05), 
30 minutes, 1, 2, 4, 8 hours (P ≤ 0.001) and 24 hours (P ≤ 0.01). U6T-20 showed 
three significant time points which were 4 hours (P ≤ 0.05), 8 hours (P ≤ 0.01) 
and 24h (P ≤ 0.001) after injection. Finally the value for the 8 hours’ time point (P 
≤ 0.05) was the only significant one found for U4T-18. 
In the fluorophotometric analysis two NPs showed superior performance in 
regard to their diffusion and half life time. Firstly, when normalized to the instant 
fluorescence, U4T-12 convinced with high values, a strong plateau phase and a 
late decrease in integrated fluorescence. This indicated strong retention of the 
NP leading to a prolonged half-life time in the vitreous body. When normalized to 
the solution measurement, strikingly U4T-12 showed weaker levels after injection 
(Figure 38). However, in the course of the graph U4T-12 constantly stayed at an 
approximate value of 20 % until after two hours, which was a time frame longer 
than for almost all other NPs except U6T-18. This consistency is what is desired 
in drug delivery to the posterior segment, which made U4T-12 one of the two 
selected NPs for further in-vivo investigations. The second NP which stands for 
superior performance is U6T-18. When normalized to the instant measured 
fluorescence, this NP already displayed great levels of intensity and a steady 
decrease over time. Compared to the solution measurement this NP was able to 
maintain the highest percentage of original fluorescence intensity of all the NPs 
by far. This indicated a strong retention in the vitreous body and a good half-life 
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time. Therefore, this NP was selected second as preferred candidate for further 
investigations. 
4.1.2. Examination of adhesion sites and variations in adhesion duration of 
DNA NPs in an ex-vivo setup 
After investigating the differences in diffusion for the different NPs, their 
adherence to ocular tissue and distribution was analyzed and compared by 
fluorescence microscopy. In order to summarize the previous observations of the 
fluorescence imaging Figure 40 displays the number of positive findings out of 
the total number of eyes that have been investigated for the specific time point. 
 
Figure 40 Number of positive eyes found out of total number of investigated eyes by 
fluorescence microscopy after intravitreal injection of NPs or control in ex-vivo porcine 
eyes. The number of positive findings out of all eyes examined for a NP is displayed at the 
bottom of the table. As is visible, the U4T-12 and U6T-18 NPs displayed the highest amount 
of positive eyes out of all tested eyes. 
The first thing to notice is that for the control out of the 15 investigated eyes none 
were found positive. This strongly supports the efficacy of the investigated NPs. 
Although the results of the fluorophotometry clearly indicated presence of 
fluorescent dye directly after injection, no signs of fluorescence can be found in 
the pictures obtained by fluorescence microscopy. The explanation for this 
negative outcome could lie in the preparation of the cryosections. Before the 
evaluation under the microscope, each slide with the sections of the respective 
eye was fixated in methanol and washed six times with buffer. Due to the low 
adhesion capacity of the dye, it was expected that this leads to total clearance of 
the control from the ocular tissue. However, this also indicated the strong 
adhesion of the different NPs that were still to be found even after the same 
procedure was followed. 
NP
Point in time Atto-488 U4T-12 U4T-18 U6T-12 U6T-18 U6T-20
5 min 0/3 3/3 2/3 2/3 2/3 2/3
15 min 0/3 3/3 3/3 2/3 3/3 2/3
30 min 0/3 2/3 2/3 3/3 3/3 2/3
1 h 0/3 3/3 2/3 3/3 3/3 3/3
2 h 0/3 3/3 3/3 3/3 3/3 3/3
Total 0/15 14/15 12/15 13/15 14/15 12/15
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From the fluorescence images it was clear that U4T-12 NPs showed the strongest 
adhesion to the retina compared to the other investigated NPs. Fluorescence 
could be observed reaching through the GCL into the INL in the one hour and 
two hours images indicating strong adherence towards the retinal tissue. This 
was underlined by the 14/15 total positive eyes that have been found. Hence, it 
can be concluded that U4T-12 NPs presented exceptional properties regarding 
their adherence and distribution towards the retinal tissue.  
Supporting the observation made in the fluorophotometric analysis, also in this 
experiment U4T-18 and U6T-20 showed inferior adhesion to the retinal tissue. 
Although the fluorescence of U4T-18 NPs could be found in the more basal parts 
of the retina such as the INL, the average fluorescence observed was much 
fainter than in U4T-12. Furthermore, NPs constructed of U6T-20 appeared less 
promising than all other investigated NPs due to weak fluorescence intensity and 
nearly non-existent coverage in the majority of the pictures. These two were the 
only NPs displaying a mere 12/15 positive eyes, which confirmed the earlier 
findings regarding their poor diffusion characteristics. Strikingly, these two NPs 
were the ones with the lowest percentage of lipid modified bases out of all 
investigated NPs. The U4T-18 and U6T-20 contained 22 % and 30 % of alkyl 
functionalized nucleotides, respectively. This could indicate that the ratio of the 
amount of lipid tails to the total amount of bases might have a profound influence 
on the diffusion behavior of the formed NPs. 
The U6T-12 NPs displayed a total of 13/15 positive results. In total U6T-12 
showed rather weak fluorescence mostly for the short incubation periods with 
incomplete covering of the retina. This was especially clear when compared to 
U4T-12 and U6T-18. Only for the two hours’ time point complete covering of the 
displayed retina was detected. Also Figure 40 stresses that U6T-12 was not as 
promising regarding adhering properties as other NPs with 13/15 positive eyes. 
Recapitulating the findings for U6T-18, one must note the high predominance of 
fluorescent NPs which was still to be found in the vitreous body even for the 
longer periods of incubation. This clearly underlined the excellent retention 
qualities of this NP. Similar as for U4T-12, also for this NP 14/15 eyes were 
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detected to be positive. However, the images showed that U6T-18 NPs also 
formed a constant coating displaying intense fluorescence on the GCL. This NP 
therefore seemed more favorable in regard to adherence properties than U4T-
18, U6T-12 and U6T-20. 
As found in fluorophotometry, the fluorescence imaging of U4T-12 and U6T-18 
showed that these NPs provide the most promising properties out of all NPs 
studied after ex-vivo intravitreal injections. Not only did they both display excellent 
coverage of the retinal tissue but they were also found to be the only NPs 
displaying 14/15 positive eyes in the ex-vivo experiments. Remarkably, these two 
NPs have the same percentage of lipid modified DNA compared to their total 
base-length (33 %). This again indicates that the amount of modified nucleotides 
might play an important role for the adherence behavior of lipid modified DNA 
NPs. Due to their superior performance the U4T-12 and U6T18 NPs were chosen 
for further in-vivo experiments. 
4.2. Intravitreal injection of lipid-modified DNA NPs into in-vivo 
rat eyes 
4.2.1. Examination of diffusion of DNA NPs within an in-vivo vitreous body 
In a first step the diffusion characteristics for two NPs and for the control were 
compared in-vivo by fluorophotometric measurement. Therefore U4T-12, U6T-18 
and Atto-488 were measured pre injection and after time points of 0, 1, 3 and 5 
days.  
One will find that compared to the results of the fluorescent microscopy which are 
discussed in the next paragraph, the data generated from the fluorophotometric 
measurements appear rather deficient. This is mainly due to methodic difficulties 
originating from working with living animals. For accurate measurements the 
optical axis of the injected eyes needed to be aligned meticulously with the optical 
axis of the Fluorotron Master™. After anesthetizing the rats, the alignment of the 
bulbus varied for each respective measurement because between those the rats 
were awake and moving. Therefore, the entire rat needed to be positioned, 
depending on the axis of the respective eye, in a different way in front of the lens 
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of the Fluorotron Master™ every time before a measurement could be 
commenced. Unfortunately, the alignment turned out to be a bigger obstacle than 
originally anticipated although trying various alignment aids. The given 
anesthesia allowed only a limited timeframe for measurements until the rat would 
wake up and further experiments would be impossible. Multiple injections of 
anesthesia held the risk of inadvertently euthanizing the animals and therefore 
losing the possibility of measuring at the very moment and later time points 
altogether. Due to these difficulties the decision was made to keep the 
fluorophotometric measurements with living rats within a limited amount in order 
to consciously avoid unnecessary animal suffering. In conclusion this means that 
the little data in “Examination of diffusion of DNA NPs within an in-vivo vitreous 
body” (3.2.1) is rather due to difficulties in accurately aligning and measuring the 
fluorescence present in the respective eye than no fluorescence being present. 
For the control and U4T-12 NPs only directly after injection measurable 
fluorescence levels were recorded, most likely due to the above mentioned 
difficulties. However, for U6T-18 NPs distinctly elevated levels of fluorescence 
were detected also the day after injection. For comparison the data obtained with 
the control has been incorporated in Figure 41, where the U6T-18 results are 
summarized. 
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Figure 41 Fluorophotometric scan of the fluorescence intensity (y axis) inside the in-vivo 
rat eye after intravitreal injection of U6T-18 along the optical axis (x axis) over time. The 
“pre injection NP” measurement showed the native eye without any treatment. The “0 days 
control” measurement has been included to stress the differences in detected 
fluorescence right after injection between NP and control dye alone due to the chemical 
modification of the dye. No other control time points were added since only this one 
showed positive findings of fluorescence. 
When comparing the U6T-18 NP with the control, two differences for the initial 0 
day measurement were found. Firstly, the detected fluorescence intensity for 
U6T-18 NPs (200 RFU) was less than half the amount of Atto-488 (500 RFU). 
This was due to the differences in fluorescence intensity of the molecules that 
have been injected. As explained in section 3.1.1 chemical modification of the 
structure of the dye can lead to alteration in fluorescence intensity. Secondly the 
peak of the U6T-18 NPs showed two shoulder peaks of around 150 RFU. This 
could be interpreted as an embodiment of the retention properties of the injected 
NP because it did not spread out steadily and evenly but was held back at the 
injection site. In the progress of the measurements these retention properties of 
the NP were also responsible for maintaining detectable traces of fluorescence 
at the injection site up to three days post application whereas the control did not 
differ in the investigations after the “0 days” time point. These results, despite the 
methodical difficulties already indicated the promising properties of the NPs and 
invited to perform further in-vivo imaging. 
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4.2.2. Examination of adhesion sites and variations in adhesion duration of 
DNA NPs in an in-vivo setup 
For the in-vivo examination of the adherence and distribution towards the retinal 
tissue a summary of the positive findings is displayed in Figure 42. 
 
Figure 42 Number of positive eyes found out of total number of investigated eyes by 
fluorescence microscopy after intravitreal injection of U4T-12, U6T-18 or control in in-vivo 
rats. The numbers of positive findings out of all eyes examined are displayed at the bottom 
of the table. Also here the U4T-12 and U6T-18 NPs displayed similarly superb results 
concerning the long-term adhesion and retention whereas the control did not exhibit any 
affinity to the retinal tissue. 
As already expected, the eyes injected with the control dye did not provide any 
positive results regarding adhesion of the fluorescent dye towards the retinal 
tissue. Neither were any other signs of fluorescence found throughout the 
prepared cryosections, leading to no positive images out of the 24 tested eyes. 
In contrast, U4T-12 and U6T-18 displayed consistent uptake of green in the 
retinal layers and the vitreous, especially for the shorter points in time. However, 
for both NPs the same tendency of strong decrease in positive findings with 
increased incubation time could be observed.  
Interestingly, as seen before in the ex-vivo images also for the in-vivo 
experiments filamentous formations of NPs could be observed in the vitreous 
body. They were found for U4T-12 in the first two points in time and for U6T-18 
at half a day and even five days. These formations were probably caused by 
adherence of the NPs towards the reticular framework of the vitreous composed 
of a network of type II collagen fibers. Interlaced into this 3D framework are 
glycosaminoglycans, hyaluronic acid and a variety of selected proteins. Further 
NP
Point in time Atto-488 U4T-12 U6T-18
½ d 0/6 5/6 5/6
1 d 0/6 4/6 4/6
3 d 0/6 3/6 4/6
5 d 0/6 1/6 1/6
Total 0/24 13/24 14/24
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research is needed for identification of the structure responsible for the observed 
NP retention. 
In conclusion, both examined NPs showed adhesion towards the retinal tissue 
for a maximum of five days. In more than 50 % of the cases NPs were found to 
be present after three days of incubation in fluorescence imaging. Additionally, 
the fluorophotometric analyses of U6T-18 confirmed the presence of NPs in the 
ocular tissue after three days of incubation. This was a strong improvement 
compared to the retention of most drugs with low molecular weights, which have 
previously been shown to have an average half-life time of only several hours39. 
Nevertheless, also the lipid-modified DNA NPs observed are subject to ocular 
clearance through the retinal tissues via passive and active transport 
mechanisms such as circulation of the aqueous humor, which may lead to 
excretion through the channel of Schlemm. However, it is expected that the NPs 
are detectable for longer periods of time than five days, but different analysis 
methods will be needed for this. Here one for example can use LC-MS. The 
limiting factors in fluorescence imaging are restricted resolution and interference 
of the background fluorescence with fluorescence of NPs. Especially the latter 
one prevented more experiments with even longer times of incubation than for 
five days because with decreasing fluorescent intensity the NPs become harder 
to differentiate from the ocular tissue’s auto fluorescence.  
4.3. Injection of lipid-modified DNA NPs into periocular tissue 
of in-vivo rat eyes 
4.3.1. Examination of adhesion sites and variations in adhesion duration of 
DNA NPs in an in-vivo setup 
Finally, also subconjunctival injections were performed in an in-vivo rat eye model 
in order to evaluate the benefit of periocular injections compared to intravitreal 
drug application. As explained before, different time points were chosen in two 
different sets. Firstly, in a short period trial only U4T-12 and the control were 
included. Afterwards a second experiment was conducted in which U4T-12, U6T-
18 and control were compared. A combined summary of both results is presented 
in Figure 43. 
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Figure 43 Number of positive fluorescence findings in the periocular tissue of the eyes out 
of total number of investigated eyes after in-vivo subconjunctival injection of U4T-12, U6T-
18 or control and subsequent fluorescence imaging. The numbers of positive findings out 
of all eyes examined are displayed at the bottom of the table. Also here the control dye 
does not show any affinity to the tissue and cannot be detected already 30 minutes post 
injection.  
For the first experiment relatively short time periods of 30 minutes, two hours and 
four hours were employed for U4T-12 NPs and the control. Here, similar 
distribution characteristics of the fluorescently labelled NPs were found in all of 
the investigated eyes. The NPs were only detectable on the outside of the bulbus, 
forming a thick fluorescent layer of variable size. The NPs covered the scleral 
tissue completely and were visible from one end of the pictured tissue to the 
other. 
For the longer time points of one and three days the findings of NP-fluorescence 
decreased in strength and spatial distribution with increasing residence time. For 
one day the images for both NPs presented area-wide and strong local 
accumulation of NPs, especially for U4T-12. After three days the green NP 
stratum only covered half of the pictured scleral surface with the fluorescent 
layers being less than 10 µm thick. Nevertheless, the numbers of total positive 
findings were still impressive. Here, all of the performed NP experiments 
displayed 5/6 positive eyes per time point, except U4T-12 which even showed 
6/6 eyes positive three days after injection.  
In contrast, none of the eyes injected with the control via the subconjunctival route 
provided evidence of positive results neither for the short nor for the long time 
periods, which supported the superior properties of the NPs. 
NP
Point in time Atto-488 U4T-12 U6T-18
30 min 0/2 2/2 -
2 h 0/2 2/2 -
4 h 0/2 2/2 -
1 d 0/2 5/6 5/6
3 d - 6/6 5/6
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The performed experiments showed that up to three days the investigated NPs 
U4T-12 and U6T-18 provide excellent adhesion towards the periocular tissue. 
From fluorescence imaging it became clear that the NPs form a covering layer on 
the scleral surface. This is also an excellent starting situation for diffusion into the 
bulbus for small molecular medication bound to the NPs. Both the long lasting 
presence and the targeting of the sclera provide excellent properties for drug 
delivery depots composed of lipid modified DNA NPs. However, for neither of the 
two NPs signs of fluorescence were found inside of the bulbus at any of the given 
time points, employing the method of fluorescence imaging. For further 
investigation in efficacy different analysis methods are necessary in order to 
overcome the limitations in resolution and background fluorescence. Due to the 
latter one, imaging for longer incubation times in subconjunctival administration 
was not possible because in the generated pictures the faint NP fluorescence 
was almost entirely overshadowed with the blue stained nuclei of the periocular 
tissue. Additionally this could mean that due to limitations in resolution for this 
method dye-fluorescence inside the bulbus might potentially have remained 
undetectable even though being present. This indicates that other methods than 
fluorescence microscopy are needed to further analyze the actual residence time 
of the NPs in the periocular tissue. Although no signs of toxicity or inflammation 
could be observed in the injected animals, further studies to confirm the retinal 
safety of the employed NPs are necessary. 
4.4. Comparison of DNA NPs to other drug delivery options for 
treatments of the posterior segment 
After highlighting the current treatment options for the therapy of intraocular 
diseases in 1.3, it is evident that the employed methods are not very efficient and 
far from ideal. A summary of those options with their respective properties is 
presented in Figure 44. 
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Figure 44 Summary of the FDA approved medication for intravitreal application for 
diseases of the posterior segment of the eye. The respective active agent, the route of 
application, the dosage, the pharmacokinetics and the biodegradability are given for 
comparison reasons.  
Anti-VEGF antibodies, like Bevacizumab, or antibody fragments such as 
Ranibizumab show intravitreal half-life times of approximately seven to ten 
days54,55, which makes multiple injections unavoidable in most cases. With a half-
life of 18.6 days56, Triamcinolone maintains significantly longer in the vitreous 
than the previously mentioned active agents but still does not provide a time 
period long enough to prevent multiple injections for the diseases highlighted in 
1.2. Although sufficiently high drug concentrations can be reached using 
intravitreal injections, frequent surgical procedures are still necessary which pose 
a large burden on the patient. A reduction of the injection frequency is highly 
desired in the field, something that might be possible using novel drug delivery 
platforms. A lower administration regimen can only be attained with prolonged 
retention of the drug in a controlled and sustained fashion. Intravitreal implants 
such as Retisert® and Iluvien® sufficiently release their active agents for an 
approximate period of 30 months57,58, however, both of them are not 
biodegradable and therefore require surgery for implantation and explantation. 
Additionally, just like the Ganciclovir implant Vitrasert®, which displays an 
Drug Active agent Application Dosage Pharmacokinetics Biodegradable
Ranibizumab
Antibody
Fragment
Intravitreal
injection
0,5 mg
Half-life time: 7.19 
days
Yes
Bevacizumab
Whole
Antibody
Intravitreal
injection
1,5 mg
Half-life time: 9.82 
days
Yes
Triamcinolone Triamcinolone
Intravitreal
injection
4 mg
Half-life time: 18.6 
days
Yes
Ozurdex® Dexamethason
Intravitreal
implant
0.7 mg
Duration of action: 
1 month
Yes
Retisert®
Fluocinolone
acetonide
Intravitreal
implant
0.59 mg
Duration of action: 
30 months
No
Iluvien®
Fluocinolone
acetonide
Intravitreal
implant
0.19 mg
Duration of action: 
24 – 36 months
No
Vitrasert®
ganciclovir 
coated with 
polyvinyl 
alcohol
Intravitreal
implant
4.5 mg
Duration of action: 
5 – 8 months
No
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intravitreal duration of action of only five to eight months59, Retisert also requires 
suturing due to its larger size after implantation60. The biodegradable Ozurdex® 
sustained-release Dexamethasone implant only requires surgery once for 
implantation, but at the same time displays a much shorter duration of efficacy 
than its non-biodegradable equivalents. In-vitro and in-vivo rabbit eye 
experiments have shown that the drug release has effectually been completed 
after approximately one month post implementation61. At least for glucocorticoids, 
implants represent an option to prolong the duration of intravitreal drug release 
and therefore reducing interventions. Yet implants are not employed for other 
than anti-inflammatory drugs and still they require rather invasive implementation. 
Ideally, a drug delivery platform also possesses targeting mechanisms to 
specifically reach the tissues of interest and minimize side effects62, which 
implants are not able to provide at this current stage. There is a vast variety of 
delivery platforms that have been investigated for their applicability in the field of 
ophthalmology. However, not all have proven as promising as they initially 
seemed. Below a selection of possible approaches has been highlighted. The 
ones displayed have been chosen in regard to relevance and innovative potential.  
 
 
4.4.1. Nanoparticles 
This work focuses on a special kind of DNA-Nanoparticles which were introduced 
in 1.4. This section elaborates on Nanoparticles in general and additionally other 
representative examples of submicron molecules which could provide progress 
in solving the problems encountered in the field of drug delivery. Subsequently 
they will be compared to our DNA-NPs. NPs may vary in size from 10 to 100 nm 
and could already be used as a launcher system for pharmaceuticals and as 
target-oriented transportation devices into diseased tissues63. In contrast to 
macroscopic objects, these sub-micron vehicles exhibit special properties due to 
their high surface area and the large influence of Brownian motion. NPs are 
providing a large potential by overcoming static diffusion barriers, which results 
in an increased ocular bioavailability. Additionally, they are also able to enhance 
the solubility of the loaded drug64,65. One of the major advantages of these 
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vehicles is that physiological barriers can be overcome and the guidance of the 
drug to intraocular compartments or even specific cells is possible through 
targeting mechanisms66,67. Polymeric nanoparticles loaded with drugs have the 
habit to reside in the target tissue for an extended period of time which generates 
a depot for the loaded medication. Drug release and degradation of the NP are 
highly dependent on the size, weight, morphology and the physical state of both 
NP and loaded drug68. Two prerequisites that such nanometer-sized vehicles 
need to fulfil are biodegradability and biocompatibility. Numerous polymeric NP 
prototypes claim to fulfil these requirements and are being tested in various 
projects69,70. Recently promising data has been acquired with a PLGA 
composition, when they were used to form NPs loaded with Dexamethasone71. 
Here, a rabbit eye model was employed to test the NP properties under in-vivo 
conditions. After intravitreal injection a sustained release of Dexamethasone was 
achieved for up to 50 days, while maintaining a nearly constant drug level for the 
first approximate 30 days. High concentrations of the released drug were found 
in the choroidea, retina and in the vitreous body. In contrast, the animal’s blood 
plasma did not contain the active ingredient, which indicates systemic side effects 
can be minimized while at the same time obtaining a higher bioavailability. 
Remarkably, the sustained release lasted approximately 20 days longer when 
PLGA NPs were employed than observed in the above described Ozurdex® 
devices. It is possible that the properties resulting from the employed polymer 
nanoobjects influence the drug release and generate longer release periods. This 
could lead to fewer injections and would therefore be highly favorable. Another 
example is given by Jo et al, which use silica NPs that already function 
themselves as active agent72. They were tested in regard to their anti-
angiogenetic impact on retinal neovascularization in oxygen induced mice and 
displayed a reduced angiogenesis whilst showing no signs of direct toxicity. 
Apparently the silica NPs cause a blockage of the VEGFR-2 pathway which in 
turn leads to the inhibition of neovascularization triggered by VEGF. This study 
illustrates that NPs could potentially function as an active agent while at the same 
time act as a carrier for drug delivery. Our DNA NPs hold the very elegant 
opportunity to be functionalized to form an oligonucleotide aptamer sequence in 
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order to target various different molecules via adaptive binding. These aptamers 
can theoretically be designed to bind VEGF and therefore block its further 
pathway. At the same time, they can be used as a delivery vehicle for a large 
variety of drugs employing one of various loading possibilities which where 
pointed out in 2.4.1. As can be seen by the examples given above, nanoscaled 
carrier platforms hold a variety of possible advantages for the field of ocular drug 
delivery. However, one should note that some portions of NPs may accumulate 
in liver, kidney and other organs73, although the risk after ocular applications 
seems to be very low. The stability and toxicity of a lot of potential NP-structures 
still needs further research especially in regard to the treatment of retinal 
diseases. In this view their accumulation and long-term toxicity may cause 
serious obstacles. Therefore, biodegradable NP formulations would be highly 
preferable. As a promising alternative for the formation of NPs from synthetic 
polymers, such vehicles can be constructed from biopolymers such as DNA in 
our case. In the course of this work different NP formulations have been 
examined. In the long-term, the aim is to refine those structures to suit the 
demands of a novel drug delivery platform.  
4.4.2. Microspheres 
Another approach to enhance effectiveness of drug administration to the eye 
involves the use of microspheres. These are globular aggregates of molecules 
with dimensions between 1 and 1000 µm that consist of a polymeric matrix in 
which the desired drug is dispersed74,75 (Figure 45). Often biodegradable 
polymers are used to ensure the degradation and clearance in the eye without 
the need of surgical removal. This is obviously an enormous advantage 
compared to non-degradable platforms. For the formation of such biodegradable 
microspheres, gelatin, albumin, polyanhydrides and polyesters are often used76. 
Here, polylactic-acids (PLA), polyglycolic-acids (PGA) and polylactic-co-glycolic-
acids (PLGA) are most frequently employed74. For the preparation of 
microspheres various methods are available. They range from denaturation, 
cross linking of macromolecules in emulsion or interfacial polymerization to 
aerosol phase formation, spray drying and pH adjustment aggregation77. 
Evaporation of a solvent from an oil in oil or oil in water emulsion is most 
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commonly used for the enclosure of drugs in a polymeric matrix. Here, the 
preparation starts with the polymer in an organic solvent added with the required 
drug. Sonication is employed to guarantee a homogeneous suspension. A drug-
polymer dispersion is used to form an emulsion before the evaporation of the 
organic solvent follows. Finally the obtained microspheres are washed with an 
inert solvent, then filtered to separate the differing sizes and dried78. With a 
complex synthesis like this, a lot of variables influence the amount of 
encapsulated drug in the microsphere, such as the physicochemical properties 
of the polymer and the drug, the used synthesis techniques and the evaporation 
rate of the solvent79. In this regard, DNA NPs have clear benefits when being 
formulated. The assembly procedure of the carrier consists of applying a simple 
heat gradient, which can be performed in virtually any lab. For production of 
polymeric microspheres however equipment allowing for interfacial 
polymerization, spray-drying or aerosol formation is required. The above 
mentioned preparation processes are rather complex and offer a lot of potential 
for variety in the amount of loaded drug, whereas for our DNA NPs, changes in 
the dosing regimen can be easily undertaken and controlled entirely in a few 
simple steps. Microspheres, consisting of the mentioned polymers are degraded 
in the aqueous environment into their components, which are eliminated from 
vitreous. Here, the speed of degradation depends on the polymer composition 
and their molecular weight, as well as the total surface area and porosity of the 
microsphere. The release of the drug is affected by the decomposition of the 
particles and additionally is dependent on diffusion of the compound through the 
polymer matrix and out of the pores of the particles78. Unfortunately, the polymer 
microspheres and especially their degradation products also hold the potential of 
causing severe side effects such as inflammation80 or retinal detachment, which 
is induced by the fibroblast activity of certain polymers81. Another potential 
drawback is the reduced stability of macromolecules due to pH drops caused by 
the acidic degradation products of polymers such as PGLA82. In the contained 
environment of the eye, such a reduced pH can cause rapid degradation of the 
polymer and therefore fast release of the drug. This negates the purpose of the 
carrier and can result in unwanted side effects. In comparison to microspherical 
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approaches, DNA NPs hold a significant advantage concerning their degradation 
profile. As the carrier is designed out of solely DNA and lipid tails, they consist of 
body own molecules that can easily be degraded in physiologic enzymatic 
degradation processes. Therefore, no adverse effects such as inflammation or 
pH drops are to be expected. Additionally, the soft nature of the micellar 
constructs minimizes the risk for retinal detachment. In the current state 
microspheres still represent an interesting platform with a lot of potential, but due 
to the above-mentioned inconveniences in regards to assembly and side effects 
their relevance in today’s treatment of retinal diseases remains virtually non-
existent. 
 
Figure 45 Structural model of a microsphere consisting of an active substance dispersed 
in a polymer matrix 
4.4.3. Ocular Implants 
Several devices which are microspheres in regard to their chemical structure 
have been approved for clinical use by the FDA and EMA and are employed as 
plugs, implants and discs75. A selection of them has already been introduced in 
1.3.2. The implants Retisert® and Iluvien® consist of a polymer matrix of polyvinyl 
alcohol and silicone that control the sustained release of the corticosteroid 
Fluocinolone acetonide for up to 30 months83,84. Due to their non-biodegradability 
these devices require not only implantation but in the case of Retisert also 
explantation which is far from ideal. To date the only biodegradable implant 
employed in for ophthalmic clinical use is Ozurdex®, which has been on the 
market since June 200985. This PLGA polymer matrix contains 700 µg 
Dexamethasone as an active agent85 and is employed in cases of macula edema 
due to RVO, diabetes and noninfectious uveitis86. Although the drug release has 
Polymeric Matrix
Drug
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been shown to be completed after approximately one month61, biodegradation 
requires an extra two months in rabbit and monkey eyes87. This results in a 
prolonged time window for possible adverse effects caused by degradation 
products whereas the active agent is only dispersed in one third of the time 
needed for biodegradation, hence in a relatively short period of efficacy versus a 
much longer period of possible adverse effects. This is not to be expected from 
our DNA NPs since their molecular formulation does not involve a complex matrix 
but rather a short and therefore easily degradable strand of ubiquitous DNA. 
Recently, also experiments were performed in which Ozurdex® was applied 
adjunct to anti VEGF treatments witch Ranibizumab in age-related macular 
degeneration. Here, no visual or anatomical benefits were observed after 
treatment with Dexamethasone in adjunct to Ranibizumab compared to the 
monotherapy with anti VEGF88. Up to date, no implants have found their way into 
the treatment of AMD and therefore the half-life time of a maximum ten days of 
Anti-VEGF antibodies or antibody fragments currently represent the limited option 
of intravitreal treatment. So far, no small molecule drug delivery therapy has been 
established for clinical use due to comparably short half-life times and 
disadvantageous side effect profiles. Here the time period of five days which was 
evident for our DNA NPs could open up new therapy options where implants are 
not available. In contrast to the above introduced implants, our NPs are able to 
be loaded with more than just a single drug, allowing treatment of multiple 
different diseases with the same carrier. If the sustained release of biodegradable 
microspheres or nanoparticles could be extended to a period close to the release 
properties of their non-degradable counterparts, this carrier type could potentially 
revolutionize ocular drug delivery to the posterior segment. So far, we were only 
able to trace DNA NP presence in the eye for a maximum of five days. However, 
these results were obtained via observation under the fluorescence microscope. 
LC-MS measurements may be able to detect longer lasting positive results in 
which case our lipid DNA NPs will be a serious alternative to biodegradable 
implants.  
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4.4.4. Liposomes 
Another promising platform for drug delivery is provided by liposomal 
formulations. Liposomes are vesicles exhibiting an aqueous core and having a 
shell formed by a lipid bilayer25 (Figure 46). In the interior water soluble drugs can 
be encapsulated. Therefore these vehicles might offer many advantages for 
intraocular drug delivery. It has already been shown in rat models that after 
injection of such liposomes they are retained in the ocular tissue for several 
weeks89,90. Here, the lower mobility of liposomes compared to the free drug allows 
an extended presence of encapsulated substances which results in an increased 
half life time of pharmaceuticals91. This reduces the necessary amount of 
injections, which in turn reduces the patient burden and the risk of complications. 
Our DNA NPs hold the option to bind medication using aptameric interactions, 
which offers a more versatile drug functionalization, compared to liposomal 
formulations. As almost any small molecule can be loaded using an aptamer, the 
carrier does not need to be adjusted to the lipophilic characteristics of the drug. 
By encapsulating labile molecules, liposomes are able to stabilize peptides92 and 
oligonucleotides93 and protect these from the harmful environment until they are 
delivered to the site of action. They can also serve to shield possible toxicity of 
the encapsulated cargo94. However, it must be noted that the toxicity of these 
carriers themselves strongly depends on their surface properties. For example, 
injections of cationic liposomes may lead to heavy inflammatory processes95. 
Another drawback of liposomes is their tendency to lead to blurry vision due to 
their larger size94. A simple benefit of the DNA-NPs is that no blurry vision after 
implementation of the nanocarriers is unlikely, as they have an approximate 
diameter of 12 nm and their solution is clear. For the formation of liposomal 
delivery vehicles, the phospholipids lecithin or phosphatidylcholine are most 
commonly used. However, addition of other molecules for their formation gives 
the potential to change the behavior of the liposomes depending on the 
respective demand. For example, cholesterol influences the viscosity of 
liposomal formulations when included in the shell. Thereby also control over the 
drug release is gained96. Furthermore, polyethylene glycol could be used to 
modify the mobility of these carriers within the vitreous body97. The different 
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composition possibilities of liposomes allow manifold modifications of the carrier 
to accommodate different drugs and regulate their release characteristics but at 
the same time this also heavily influences their surface properties and therefore 
their toxicity profile. In contrast, the NPs examined in this thesis are constituted 
out of a single amphiphilic oligonucleotide. Due to this and the excellent 
biodegradability, no large variation in their safety is to be expected upon loading 
of different medication. Besides all of the mentioned advantages of liposomal 
formulations, so far none have been released on the market for intravitreal 
application. The only example relevant to ophthalmology is Visudyne, which is 
employed for the treatment of predominantly subfoveal choroidal 
neovascularization, mainly in cases of AMD. However, this liposome containing 
solution is not applied intravitreally, but requires intravenous administration94. The 
liposomal structure is necessary to dissolve the hydrophobic active agent 
verteporin for injection purposes. After reaching the choroida and the neovascular 
vessels via systemic blood circulation, the drug may be activated using a non-
thermal laser. This procedure results in selective occlusion of the targeted blood 
vessels, which in turn leads to a decrease in exudation and bleeding98. However, 
photodynamic treatment concepts involving medication like Visudyne have  been 
reported to hold risks of immediate visual loss and adverse effects due to the 
occluding properties of the carrier99 Moreover, the efficacy of photodynamic 
treatment in neovascular AMD is inferior to anti-VEGF therapy. 
 
Figure 46 Example of liposome displaying a single phospholipid bilayer without any further 
structural modification 
4.4.5. Dendrimers 
Dendrimers are spherical multi-branched polymers of a size between 3-20 nm100. 
They consist of an inner “core” from which branching chains reach out to 
Aqueous
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peripheral multivalent moieties101. By chemical modification of a dendrimer’s 
structure, the drug loading as well as the release can be adjusted102. Their 
chemical structure, size and therefore their physical properties can be designed 
on the molecular level103. The functional groups of dendrimers can be used for 
drug loading via lipophilic or ionic interactions and covalent bonds. However, only 
lower amounts of drugs can be incorporated compared to other carriers, such as 
liposomes, microspheres and nanocarriers98. This means that higher 
concentrations of dendrimers are needed to deliver the same amount of drug as 
a DNA NP at lower concentrations. Strikingly, only little work has been published 
regarding the toxicity of dendrimers, offering unsatisfactory results. To date, there 
is still only fragmentary in-vivo animal investigations and no published clinical 
data for the ocular use of dendrimers in humans104. Regarding treatments for 
diseases located in the posterior segment of the eye, dendrimers designed out of 
biodegradable polymers are highly desirable. Recently, there has been reported 
synthesis and characterization of biodegradable dendrimers composed out of 
biocompatible polyamides105,106. Although it has been proven in cytotoxicity 
studies that these dendrimers are non-toxic, they are not employed in tests for 
use in the posterior segment of the eye so far. As for non-biodegradable 
dendrimers, one of the species most commonly referred to is a polyamidoamin 
(PAMAM) dendrimer. Due to advantageous solubility and no immunogenicity107 
this formulation has been well characterized and closely investigated. Besides 
the fact that some PAMAM dendrimers are toxic in cells and animals104, they have 
been employed for several studies including intravitreal injections into the 
posterior segment of the eye108,109. Guo et al. were able to proof that cyanine dye-
conjugated OH-PAMAM dendrimers remained in the rat eye vitreous for up to two 
days, originally applied for the reason of targeting ischemia lesions. Also 
regarding retention, our DNA NPs display more promising results, lasting in the 
eye for up to five days. Similar to the earlier introduced microspheres, dendrimers 
are primarily the subject of research. They have not found their way into clinical 
treatment of retinal diseases yet most likely due to insufficient loading and more 
importantly unsatisfactory toxicity results.  
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4.5. Prospects for further research 
On one hand special attributes of NPs due to sub-micron properties hold a lot of 
potential for medical treatment in the future. On the other the effects of our body 
are yet inadequately understood. Long time toxicity analysis with special focus 
on the effect of the Brownian motion and diffusion barriers are necessary. NP 
molecules have been known to cause immune reactions when brought into the 
human body110. Research shows that nanomaterials can stimulate and/or 
suppress the immune responses, and that their compatibility with the immune 
system is largely determined by their surface properties. NP size, composition, 
surface chemistry, surface charge, hydrophobicity, shape, administration routes 
and protein binding tendency seem to be the main factors that contribute to the 
interactions of NPs with the immune system111-113. It is important to understand 
the immunological effect that the DNA NPs could have on the human body. Due 
to the very short sequences of the DNA-strands that were employed in our 
manufactured NPs immunological interactions are unlikely, but nevertheless 
need to be ruled out entirely. After confirming the safety of the NPs, the loading 
with medication needs to be commenced. Here, several options exist, as outlined 
in section 1.4. Upon conformation of the functionalization of the carrier, several 
in-vivo pharmacokinetic studies employing LC-MS studies should be performed 
to analyze the half-life time of the applied drug in different structures of the ocular 
cavity. Finally, the efficacy of the delivered pharmaceutical agents should be 
confirmed in a diseased animal model. Here, the beneficial delivery properties of 
the NP platform hopefully should result in prolonged effects of the drug or open 
the possibility of attaining a lower dosing regimen.  
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5. Conclusion 
The tissue in the posterior segment of the eye remains a difficult target site in 
regard to ocular drug delivery. Therefore diseases, such as AMD, DME and RVO 
are difficult to treat and therapy is associated with numerous side effects. 
Currently, intravitreal injections or topical drug application result in only a limited 
duration time of the active agent in the eye and therefore lack efficiency. A novel 
method of drug delivery is desirable in order to enhance the performance of local 
treatments and reduce side effects as much as possible. Here, the application of 
NPs consisting of DNA micelles offers a promising platform for future drug 
delivery. In this thesis it was shown that these lipid-modified DNA NPs meet the 
criteria needed for drug delivery to the posterior segment. Firstly, the efficient 
retention of the NPs in the vitreous body of ex-vivo porcine eyes was 
demonstrated, promising prolonged drug release in the ocular space. Secondly, 
these novel vehicles also showed excellent adhesion towards the retinal tissue, 
which was also verified in ex-vivo animal models. These targeting properties 
could lead to increased efficacy of the employed drugs and therefore offer the 
possibility to reduce the necessary drug concentrations. Both of these important 
properties were observed in several of the NPs that were tested. In particular the 
U4T-12 and U6T-18 NPs displayed superior characteristics in the ex-vivo setup 
(the “U” followed by a number stands for the amount of lipid modified deoxyuridine 
bases, which are located at the 5’-end of the NP base sequence; the second 
number in this code indicates the total amount of nucleotides in the NP) and were 
therefore employed in further in-vivo investigations. Efficient retention in the 
vitreous body was evident up to three days and the presence of the NPs could 
be confirmed in treated eyes up to five days in in-vivo experiments. To explore 
the use of alternative application routes, both prioritized NPs were also applied in 
living rats via subconjunctival injections. Here, the results indicate even more 
promising properties regarding the retention in the analyzed tissues. The NPs 
were notably accumulating on the scleral surface of the eyes. To conclude, we 
have shown here that the use of our NPs could lead to sufficient intraocular drug 
concentration for several days, preventing unneeded intravitreal injections and 
establishing this route of admission for small molecule active agents. These 
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promising results invite to conduct further research regarding the efficacy of 
delivered medication and establish DNA based NPs as a drug delivery platform 
for the posterior segment. 
6. Zusammenfassung 
Drug Delivery in die Region des hinteren Augensegments stellt die 
Augenheilkunde vor eklatante Schwierigkeiten. Krankheitsbilder wie die 
altersbedingte Makuladegeneration, das diabetische Makulaödem und der 
retinale Venenverschluss sind immer noch schwer behandelbar und die 
Therapien meist mit Nebenwirkungen verbunden. Derzeitige Therapieoptionen, 
wie beispielsweise intravitreale Injektionen oder die topische Anwendung der 
Wirkstoffe führen zu sehr kurzweiliger Präsenz der Medikation im Auge und somit 
nur zu unzufriedenstellender Effektivität. Wünschenswert wäre eine 
Verlängerung der Wirksamkeit lokaler Behandlungen und eine Minimierung der 
Nebenwirkungen. Nanopartikel, aufgebaut aus DNA-Mizellen bieten hier eine 
vielversprechende Plattformtechnologie. Die erfolgreiche Retention des 
Nanopartikels im Glaskörper eines ex-vivo Schweineaugenmodells wurde 
demonstriert, was eine verlängerte Wirkstofffreigabe verspricht. Weiterhin zeigt 
die neue Plattformtechnik exzellente Bindungseigenschaften für das retinale 
Gewebe, ebenfalls im ex-vivo Modell verifiziert. Sowohl die längere Retention als 
auch die Adhäsion zur Retina wurde bei verschiedenen getesteten Nanopartikeln 
beobachtet. Besonders fielen hierbei U4T-12 und U6T-18 durch überlegene 
Eigenschaften in den ex-vivo Experimenten auf (das „U“ mit nachfolgender Ziffer 
steht für die Anzahl an lipidmodifizierten Desoxyuridinbasen, welche am 5‘-
Terminus „T“ der Nukleotidabfolge des DNA Nanopartikels angeordnet sind; die 
zweite Zahl im Bezeichnungscode steht für die Gesamtzahl an Nukleotiden des 
Nanopartikel), was sie für nachfolgende in-vivo Untersuchungen qualifizierte. Bis 
zu drei Tage nach der Applikation zeigte sich effektive Retention und bis zu fünf 
Tage danach waren Nanopartikel nachweisbar. Zur Untersuchung verschiedener 
Applikationsmethoden wurden beide priorisierten Nanopartikel auch in das 
periokuläre Gewebe lebender Ratten mittels subkonjunktivaler Injektion 
eingebracht. Die Retention war hier noch deutlicher in Form von Ansammlungen 
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auf der Außenseite der Sklera zu beobachten. Zusammenfassend waren wir in 
der Lage zu zeigen, dass an Nanopartikel gebundene Medikamentendepots zu 
suffizienten intraokularen Wirkstoffkonzentrationen für mehrere Tage führen 
können um somit ggf. intravitreale Injektionen zu minimieren oder bei kleineren 
Wirkstoffmolekülen überhaupt erst zu ermöglichen. Diese vielversprechenden 
Ergebnisse laden zu weiteren Untersuchungen ein um die lipid-modifizierten 
DNA Nanopartikel als Drug Delivery System für das hintere Segment des Auges 
zu etablieren.  
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